EuRBPDB

Basic Information
Cancer Related Information

Description

RBDs

Literatures

Expression

Transcripts

Gene Model

Pathways

Phenotypes

PPI

Orthologs

Gene Ontology

Description

Ensembl ID: ENSG00000133703 (Gene tree)
Gene ID: 3845
Gene Symbol: KRAS
Alias: KRAS1|KRAS2
Full Name: KRAS proto-oncogene, GTPase
Gene Type: protein_coding
Species: Homo_sapiens
Status: confidence
Strand: Minus strand
Length: 46,148 bases
Position: chr12:25,204,789-25,250,936
Accession: 6407
RBP type: canonical RBP
Summary: This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region. [provided by RefSeq, Jul 2008]

RNA binding domains(RBDs)

Protein ID	Domain	Pfam ID	E-value	Domain number	Total number
ENSP00000308495	GTP_EFTU	PF00009.27	1.5e-06	1	1
ENSP00000308495	MMR_HSR1	PF01926.23	7.6e-05	1	1
ENSP00000256078	MMR_HSR1	PF01926.23	0.0001	1	1

Literatures on RNA binding capacity

PID	Title	Article	Time	Author	Doi
22910295	Inhibition of the interaction between NS3 protease and HCV IRES with a small peptide: a novel therapeutic strategy.	Mol Ther	2013 Jan	Ray U	doi: 10.1038/mt.2012.151
26852652	ETV6/RUNX1 transcript is a target of RNA-binding protein IGF2BP1 in t(12;21)(p13;q22)-positive acute lymphoblastic leukemia.	Blood Cells Mol Dis	2016 Mar	Stoskus M	doi: 10.1016/j.bcmd.2015.11.006
17319155	Multiple enzyme activities of flavivirus proteins.	Novartis Found Symp	2006	Padmanabhan R	-
23986595	A host YB-1 ribonucleoprotein complex is hijacked by hepatitis C virus for the control of NS3-dependent particle production.	J Virol	2013 Nov	Chatel-Chaix L	doi: 10.1128/JVI.01474-13
9657959	Recombinant dengue virus type 1 NS3 protein exhibits specific viral RNA binding and NTPase activity regulated by the NS5 protein.	Virology	1998 Jul 5	Cui T	-
8893335	Signal transduction as target of gene therapy.	Recent Results Cancer Res	1996	Moelling K	-
7978859	Stimulation of Ki-ras ribozyme activity by RNA binding protein, NCp7, in vitro and in pancreatic tumor cell line, capan 1.	Ann N Y Acad Sci	1994 Sep 15	Moelling K	-
23359228	Psammaplin A inhibits hepatitis C virus NS3 helicase.	J Nat Med	2013 Oct	Salam KA	doi: 10.1007/s11418-013-0742-7
22394195	Inhibition of hepatitis C virus NS3 helicase by manoalide.	J Nat Prod	2012 Apr 27	Salam KA	doi: 10.1021/np200883s
22355520	Interplay between NS3 protease and human La protein regulates translation-replication switch of Hepatitis C virus.	Sci Rep	2011	Ray U	doi: 10.1038/srep00001
20951141	Size-independent and noncooperative recognition of dsRNA by the Rice stripe virus RNA silencing suppressor NS3.	J Mol Biol	2010 Dec 10	Shen M	doi: 10.1016/j.jmb.2010.10.007
24965468	The linker region of NS3 plays a critical role in the replication and infectivity of hepatitis C virus.	J Virol	2014 Sep	Kohlway A	doi: 10.1128/JVI.00745-14
24372207	Recent highlights in the synthesis of anti-HCV ribonucleosides.	Curr Med Chem	2014	Piperno A	-
28341122	Molecular dynamics simulations of Zika virus NS3 helicase: Insights into RNA binding site activity.	Biochem Biophys Res Commun	2017 Oct 28	Mottin M	doi: 10.1016/j.bbrc.2017.03.070
27273003	The role of surface basic amino acids of dengue virus NS3 helicase in viral RNA replication and enzyme activities.	FEBS Lett	2016 Jul	Chiang PY	doi: 10.1002/1873-3468.12232
29165589	NS3 helicase from dengue virus specifically recognizes viral RNA sequence to ensure optimal replication.	Nucleic Acids Res	2017 Dec 15	Swarbrick CMD	doi: 10.1093/nar/gkx1127.
19282433	Binding of small interfering RNA molecules is crucial for RNA interference suppressor activity of rice hoja blanca virus NS3 in plants.	J Gen Virol	2009 Jul	Hemmes H	doi: 10.1099/vir.0.010488-0
21849455	Y-box-binding protein 1 interacts with hepatitis C virus NS3/4A and influences the equilibrium between viral RNA replication and infectious particle production.	J Virol	2011 Nov	Chatel-Chaix L	doi: 10.1128/JVI.00719-11
24623306	A KRAS-directed transcriptional silencing pathway that mediates the CpG island methylator phenotype.	Elife	2014 Mar 12	Serra RW	doi: 10.7554/eLife.02313.
24521262	Cationic lipid-assisted polymeric nanoparticle mediated GATA2 siRNA delivery for synthetic lethal therapy of KRAS mutant non-small-cell lung carcinoma.	Mol Pharm	2014 Aug 4	Shen S	doi: 10.1021/mp400714z
9356339	Isolation of RNA aptamers specific to the NS3 protein of hepatitis C virus from a pool of completely random RNA.	Virology	1997 Oct 27	Kumar PK	-
11160669	Specific interaction of hepatitis C virus protease/helicase NS3 with the 3'-terminal sequences of viral positive- and negative-strand RNA.	J Virol	2001 Feb	Banerjee R	-
15289579	Enhanced nucleic acid binding to ATP-bound hepatitis C virus NS3 helicase at low pH activates RNA unwinding.	Nucleic Acids Res	2004 Aug 2	Lam AM	-
18089758	The NS3 protein of rice hoja blanca virus suppresses RNA silencing in mammalian cells.	J Gen Virol	2008 Jan	Schnettler E	-
20637813	Classical swine fever virus NS3 is an IRES-binding protein and increases IRES-dependent translation.	Virus Res	2010 Oct	Zhu Z	doi: 10.1016/j.virusres.2010.07.013
25579590	Mechanisms of HCV NS3 helicase monitored by optical tweezers.	Methods Mol Biol	2015	Cheng W	doi: 10.1007/978-1-4939-2214-7_15.
27992614	A Single Nucleotide Polymorphism in the RASGRF2 Gene Is Associated with Alcoholic Liver Cirrhosis in Men.	PLoS One	2016 Dec 19	Novo-Veleiro I	doi: 10.1371/journal.pone.0168685
26945984	Long non-coding RNA GAS5 inhibited hepatitis C virus replication by binding viral NS3 protein.	Virology	2016 May	Qian X	doi: 10.1016/j.virol.2016.02.020

Expression

Transcripts

Transcript ID	Name	Length	RefSeq ID	Protein ID	Length	RefSeq ID	UniportKB ID
ENST00000311936	KRAS-202	5765	XM_011520653	ENSP00000308495	188 (aa)	XP_011518955	P01116
ENST00000256078	KRAS-201	1119	XM_006719069	ENSP00000256078	189 (aa)	XP_006719132	P01116
ENST00000556131	KRAS-203	1696	-	ENSP00000451856	43 (aa)	-	G3V4K2
ENST00000557334	KRAS-204	1052	-	ENSP00000452512	75 (aa)	-	G3V5T7

Gene Model

Click here to download ENSG00000133703's gene model file

Pathways

Pathway ID	Pathway Name	Source
hsa01521	EGFR tyrosine kinase inhibitor resistance	KEGG
hsa01522	Endocrine resistance	KEGG
hsa04010	MAPK signaling pathway	KEGG
hsa04012	ErbB signaling pathway	KEGG
hsa04014	Ras signaling pathway	KEGG
hsa04015	Rap1 signaling pathway	KEGG
hsa04062	Chemokine signaling pathway	KEGG
hsa04068	FoxO signaling pathway	KEGG
hsa04071	Sphingolipid signaling pathway	KEGG
hsa04072	Phospholipase D signaling pathway	KEGG
hsa04137	Mitophagy - animal	KEGG
hsa04140	Autophagy - animal	KEGG
hsa04150	mTOR signaling pathway	KEGG
hsa04151	PI3K-Akt signaling pathway	KEGG
hsa04210	Apoptosis	KEGG
hsa04211	Longevity regulating pathway	KEGG
hsa04213	Longevity regulating pathway - multiple species	KEGG
hsa04218	Cellular senescence	KEGG
hsa04360	Axon guidance	KEGG
hsa04370	VEGF signaling pathway	KEGG
hsa04371	Apelin signaling pathway	KEGG
hsa04540	Gap junction	KEGG
hsa04550	Signaling pathways regulating pluripotency of stem cells	KEGG
hsa04625	C-type lectin receptor signaling pathway	KEGG
hsa04650	Natural killer cell mediated cytotoxicity	KEGG
hsa04660	T cell receptor signaling pathway	KEGG
hsa04662	B cell receptor signaling pathway	KEGG
hsa04664	Fc epsilon RI signaling pathway	KEGG
hsa04714	Thermogenesis	KEGG
hsa04720	Long-term potentiation	KEGG
hsa04722	Neurotrophin signaling pathway	KEGG
hsa04725	Cholinergic synapse	KEGG
hsa04726	Serotonergic synapse	KEGG
hsa04730	Long-term depression	KEGG
hsa04810	Regulation of actin cytoskeleton	KEGG
hsa04910	Insulin signaling pathway	KEGG
hsa04912	GnRH signaling pathway	KEGG
hsa04914	Progesterone-mediated oocyte maturation	KEGG
hsa04915	Estrogen signaling pathway	KEGG
hsa04916	Melanogenesis	KEGG
hsa04917	Prolactin signaling pathway	KEGG
hsa04919	Thyroid hormone signaling pathway	KEGG
hsa04921	Oxytocin signaling pathway	KEGG
hsa04926	Relaxin signaling pathway	KEGG
hsa04933	AGE-RAGE signaling pathway in diabetic complications	KEGG
hsa04960	Aldosterone-regulated sodium reabsorption	KEGG
hsa05034	Alcoholism	KEGG
hsa05160	Hepatitis C	KEGG
hsa05161	Hepatitis B	KEGG
hsa05163	Human cytomegalovirus infection	KEGG
hsa05165	Human papillomavirus infection	KEGG
hsa05166	Human T-cell leukemia virus 1 infection	KEGG
hsa05167	Kaposi sarcoma-associated herpesvirus infection	KEGG
hsa05170	Human immunodeficiency virus 1 infection	KEGG
hsa05200	Pathways in cancer	KEGG
hsa05203	Viral carcinogenesis	KEGG
hsa05205	Proteoglycans in cancer	KEGG
hsa05206	MicroRNAs in cancer	KEGG
hsa05210	Colorectal cancer	KEGG
hsa05211	Renal cell carcinoma	KEGG
hsa05212	Pancreatic cancer	KEGG
hsa05213	Endometrial cancer	KEGG
hsa05214	Glioma	KEGG
hsa05215	Prostate cancer	KEGG
hsa05216	Thyroid cancer	KEGG
hsa05218	Melanoma	KEGG
hsa05219	Bladder cancer	KEGG
hsa05220	Chronic myeloid leukemia	KEGG
hsa05221	Acute myeloid leukemia	KEGG
hsa05223	Non-small cell lung cancer	KEGG
hsa05224	Breast cancer	KEGG
hsa05225	Hepatocellular carcinoma	KEGG
hsa05226	Gastric cancer	KEGG
hsa05230	Central carbon metabolism in cancer	KEGG
hsa05231	Choline metabolism in cancer	KEGG

Phenotypes

ensgID	Trait	pValue	Pubmed ID
ENSG00000133703	Heart Diseases	1.9539376742651E-5	17903304
ENSG00000133703	Heart Diseases	1.34228670028596E-5	17903304
ENSG00000133703	Neuroblastoma	1.43e-005	23222812
ENSG00000133703	Platelet Function Tests	6.6400000E-006	-
ENSG00000133703	Liver Cirrhosis, Biliary	4.1100000E-006	20639880
ENSG00000133703	Dysmenorrhea	6E-7	27454463
ENSG00000133703	Alzheimer Disease	8E-7	27770636
ENSG00000133703	Glucose	6E-6	23400010
ENSG00000133703	Hydrochlorothiazide	6E-6	23400010

Protein-Protein Interaction (PPI)

Clik here to download ENSG00000133703's network

* RBP PPI network refers to all genes directly bind to RBP

Orthologs

Ensembl ID	Gene Symbol	Coverage	Identiy	Ortholog	Gene Symbol	Coverage	Identiy	Species
ENSG00000133703	KRAS	100	100.000	ENSAPOG00000014783	kras	100	98.404	Acanthochromis_polyacanthus
ENSG00000133703	KRAS	100	98.942	ENSAMEG00000007529	KRAS	100	98.942	Ailuropoda_melanoleuca
ENSG00000133703	KRAS	99	95.722	ENSACIG00000000100	kras	62	95.213	Amphilophus_citrinellus
ENSG00000133703	KRAS	100	100.000	ENSAOCG00000017428	kras	100	98.404	Amphiprion_ocellaris
ENSG00000133703	KRAS	100	100.000	ENSAPEG00000007675	kras	100	98.404	Amphiprion_percula
ENSG00000133703	KRAS	100	100.000	ENSATEG00000021300	kras	100	98.404	Anabas_testudineus
ENSG00000133703	KRAS	100	100.000	ENSAPLG00000015953	KRAS	100	98.936	Anas_platyrhynchos
ENSG00000133703	KRAS	91	95.349	ENSACAG00000017404	-	100	87.831	Anolis_carolinensis
ENSG00000133703	KRAS	100	100.000	ENSACAG00000016948	-	100	98.936	Anolis_carolinensis
ENSG00000133703	KRAS	100	100.000	ENSANAG00000030296	KRAS	100	100.000	Aotus_nancymaae
ENSG00000133703	KRAS	100	98.404	ENSACLG00000027677	KRAS	100	96.296	Astatotilapia_calliptera
ENSG00000133703	KRAS	100	98.404	ENSACLG00000027515	KRAS	100	96.296	Astatotilapia_calliptera
ENSG00000133703	KRAS	100	100.000	ENSAMXG00000017217	kras	100	98.404	Astyanax_mexicanus
ENSG00000133703	KRAS	100	100.000	ENSBTAG00000009778	KRAS	100	99.471	Bos_taurus
ENSG00000133703	KRAS	100	100.000	ENSCJAG00000044757	KRAS	100	100.000	Callithrix_jacchus
ENSG00000133703	KRAS	100	100.000	ENSCAFG00000011428	KRAS	100	99.468	Canis_familiaris
ENSG00000133703	KRAS	100	100.000	ENSCAFG00020012793	KRAS	100	99.468	Canis_lupus_dingo
ENSG00000133703	KRAS	100	100.000	ENSCHIG00000026575	KRAS	100	99.471	Capra_hircus
ENSG00000133703	KRAS	100	100.000	ENSTSYG00000032750	KRAS	100	100.000	Carlito_syrichta
ENSG00000133703	KRAS	100	100.000	ENSCPOG00000030290	KRAS	100	100.000	Cavia_porcellus
ENSG00000133703	KRAS	100	100.000	ENSCCAG00000031963	KRAS	100	100.000	Cebus_capucinus
ENSG00000133703	KRAS	100	100.000	ENSCATG00000030021	KRAS	100	100.000	Cercocebus_atys
ENSG00000133703	KRAS	100	100.000	ENSCLAG00000016519	KRAS	100	100.000	Chinchilla_lanigera
ENSG00000133703	KRAS	100	100.000	ENSCSAG00000007777	KRAS	100	100.000	Chlorocebus_sabaeus
ENSG00000133703	KRAS	86	100.000	ENSCPBG00000015094	-	100	87.831	Chrysemys_picta_bellii
ENSG00000133703	KRAS	100	100.000	ENSCPBG00000009289	-	100	98.936	Chrysemys_picta_bellii
ENSG00000133703	KRAS	100	100.000	ENSCANG00000021664	KRAS	100	100.000	Colobus_angolensis_palliatus
ENSG00000133703	KRAS	100	100.000	ENSCGRG00001006529	-	100	99.471	Cricetulus_griseus_chok1gshd
ENSG00000133703	KRAS	100	93.122	ENSCGRG00001013183	-	100	93.122	Cricetulus_griseus_chok1gshd
ENSG00000133703	KRAS	100	100.000	ENSCGRG00000015400	-	100	98.942	Cricetulus_griseus_crigri
ENSG00000133703	KRAS	100	100.000	ENSCSEG00000005737	kras	100	97.872	Cynoglossus_semilaevis
ENSG00000133703	KRAS	100	100.000	ENSCVAG00000006062	KRAS	100	96.809	Cyprinodon_variegatus
ENSG00000133703	KRAS	100	100.000	ENSDARG00000010844	kras	100	96.277	Danio_rerio
ENSG00000133703	KRAS	100	100.000	ENSDNOG00000046741	KRAS	100	99.468	Dasypus_novemcinctus
ENSG00000133703	KRAS	100	98.413	ENSDORG00000011469	-	100	98.413	Dipodomys_ordii
ENSG00000133703	KRAS	100	98.413	ENSETEG00000002355	KRAS	100	98.413	Echinops_telfairi
ENSG00000133703	KRAS	100	100.000	ENSEBUG00000015012	kras	100	90.957	Eptatretus_burgeri
ENSG00000133703	KRAS	100	97.340	ENSEASG00005001110	-	100	97.340	Equus_asinus_asinus
ENSG00000133703	KRAS	100	100.000	ENSEASG00005013898	KRAS	100	98.936	Equus_asinus_asinus
ENSG00000133703	KRAS	100	99.471	ENSECAG00000019522	KRAS	100	99.471	Equus_caballus
ENSG00000133703	KRAS	100	95.745	ENSECAG00000030195	-	100	95.745	Equus_caballus
ENSG00000133703	KRAS	100	97.884	ENSEEUG00000003058	KRAS	100	97.884	Erinaceus_europaeus
ENSG00000133703	KRAS	100	100.000	ENSELUG00000003058	KRAS	100	98.404	Esox_lucius
ENSG00000133703	KRAS	100	100.000	ENSFCAG00000026808	KRAS	100	99.468	Felis_catus
ENSG00000133703	KRAS	100	100.000	ENSFALG00000003867	KRAS	100	98.936	Ficedula_albicollis
ENSG00000133703	KRAS	100	100.000	ENSFDAG00000000107	KRAS	100	99.471	Fukomys_damarensis
ENSG00000133703	KRAS	100	100.000	ENSFHEG00000009108	kras	100	97.872	Fundulus_heteroclitus
ENSG00000133703	KRAS	100	93.122	ENSGMOG00000010581	kras	99	93.122	Gadus_morhua
ENSG00000133703	KRAS	100	100.000	ENSGALG00000030943	KRAS	100	98.936	Gallus_gallus
ENSG00000133703	KRAS	100	100.000	ENSGAFG00000021765	kras	100	98.404	Gambusia_affinis
ENSG00000133703	KRAS	100	95.238	ENSGACG00000011661	kras	98	95.238	Gasterosteus_aculeatus
ENSG00000133703	KRAS	91	95.322	ENSGAGG00000011790	-	100	87.831	Gopherus_agassizii
ENSG00000133703	KRAS	100	100.000	ENSGAGG00000011057	KRAS	100	98.936	Gopherus_agassizii
ENSG00000133703	KRAS	100	100.000	ENSGGOG00000008043	KRAS	100	100.000	Gorilla_gorilla
ENSG00000133703	KRAS	100	100.000	ENSHBUG00000013197	kras	100	98.936	Haplochromis_burtoni
ENSG00000133703	KRAS	100	100.000	ENSHGLG00000008775	KRAS	100	100.000	Heterocephalus_glaber_female
ENSG00000133703	KRAS	100	100.000	ENSHGLG00100008637	KRAS	100	100.000	Heterocephalus_glaber_male
ENSG00000133703	KRAS	100	100.000	ENSHCOG00000011080	kras	100	98.404	Hippocampus_comes
ENSG00000133703	KRAS	100	100.000	ENSIPUG00000004259	kras	100	98.404	Ictalurus_punctatus
ENSG00000133703	KRAS	100	100.000	ENSSTOG00000009530	KRAS	100	99.471	Ictidomys_tridecemlineatus
ENSG00000133703	KRAS	100	100.000	ENSJJAG00000016513	-	100	99.471	Jaculus_jaculus
ENSG00000133703	KRAS	100	100.000	ENSKMAG00000003938	kras	100	97.872	Kryptolebias_marmoratus
ENSG00000133703	KRAS	100	100.000	ENSLBEG00000028450	kras	100	98.404	Labrus_bergylta
ENSG00000133703	KRAS	100	100.000	ENSLACG00000017464	KRAS	100	99.471	Latimeria_chalumnae
ENSG00000133703	KRAS	73	92.701	ENSLACG00000010885	-	91	89.928	Latimeria_chalumnae
ENSG00000133703	KRAS	100	100.000	ENSLOCG00000015334	kras	100	98.936	Lepisosteus_oculatus
ENSG00000133703	KRAS	100	100.000	ENSLAFG00000029239	KRAS	100	99.468	Loxodonta_africana
ENSG00000133703	KRAS	100	100.000	ENSMFAG00000003804	KRAS	100	100.000	Macaca_fascicularis
ENSG00000133703	KRAS	100	100.000	ENSMMUG00000015381	KRAS	100	100.000	Macaca_mulatta
ENSG00000133703	KRAS	100	100.000	ENSMNEG00000045179	KRAS	100	100.000	Macaca_nemestrina
ENSG00000133703	KRAS	100	100.000	ENSMLEG00000028386	KRAS	100	100.000	Mandrillus_leucophaeus
ENSG00000133703	KRAS	100	100.000	ENSMAMG00000005606	kras	100	98.404	Mastacembelus_armatus
ENSG00000133703	KRAS	100	100.000	ENSMZEG00005017913	kras	100	98.936	Maylandia_zebra
ENSG00000133703	KRAS	100	100.000	ENSMGAG00000013673	KRAS	100	98.936	Meleagris_gallopavo
ENSG00000133703	KRAS	100	100.000	ENSMAUG00000017232	Kras	100	100.000	Mesocricetus_auratus
ENSG00000133703	KRAS	100	100.000	ENSMOCG00000011313	Kras	100	99.471	Microtus_ochrogaster
ENSG00000133703	KRAS	97	97.802	ENSMMOG00000017479	kras	97	97.802	Mola_mola
ENSG00000133703	KRAS	100	100.000	ENSMODG00000025248	-	100	98.936	Monodelphis_domestica
ENSG00000133703	KRAS	100	100.000	ENSMODG00000017458	KRAS	100	99.468	Monodelphis_domestica
ENSG00000133703	KRAS	100	97.872	ENSMALG00000010781	kras	100	97.872	Monopterus_albus
ENSG00000133703	KRAS	100	100.000	MGP_CAROLIEiJ_G0029047	Kras	100	98.942	Mus_caroli
ENSG00000133703	KRAS	100	100.000	ENSMUSG00000030265	Kras	100	98.942	Mus_musculus
ENSG00000133703	KRAS	100	100.000	MGP_PahariEiJ_G0022808	Kras	100	98.942	Mus_pahari
ENSG00000133703	KRAS	100	100.000	MGP_SPRETEiJ_G0030102	Kras	100	98.942	Mus_spretus
ENSG00000133703	KRAS	86	100.000	ENSMPUG00000010291	KRAS	78	94.479	Mustela_putorius_furo
ENSG00000133703	KRAS	100	100.000	ENSMLUG00000015948	KRAS	100	100.000	Myotis_lucifugus
ENSG00000133703	KRAS	100	100.000	ENSNGAG00000000727	Kras	100	98.413	Nannospalax_galili
ENSG00000133703	KRAS	100	100.000	ENSNBRG00000004403	kras	100	98.936	Neolamprologus_brichardi
ENSG00000133703	KRAS	100	100.000	ENSNLEG00000027684	KRAS	100	100.000	Nomascus_leucogenys
ENSG00000133703	KRAS	100	100.000	ENSOPRG00000012068	KRAS	100	100.000	Ochotona_princeps
ENSG00000133703	KRAS	100	100.000	ENSODEG00000010412	KRAS	100	100.000	Octodon_degus
ENSG00000133703	KRAS	100	100.000	ENSONIG00000014717	kras	100	98.936	Oreochromis_niloticus
ENSG00000133703	KRAS	100	100.000	ENSOANG00000009650	KRAS	100	99.468	Ornithorhynchus_anatinus
ENSG00000133703	KRAS	100	98.942	ENSOCUG00000012106	KRAS	78	98.942	Oryctolagus_cuniculus
ENSG00000133703	KRAS	100	100.000	ENSORLG00000024102	kras	100	97.340	Oryzias_latipes
ENSG00000133703	KRAS	100	100.000	ENSORLG00020020961	kras	100	97.340	Oryzias_latipes_hni
ENSG00000133703	KRAS	100	100.000	ENSORLG00015011467	kras	100	97.340	Oryzias_latipes_hsok
ENSG00000133703	KRAS	100	100.000	ENSOMEG00000011273	kras	100	97.340	Oryzias_melastigma
ENSG00000133703	KRAS	100	100.000	ENSOGAG00000014812	KRAS	100	99.468	Otolemur_garnettii
ENSG00000133703	KRAS	100	100.000	ENSOARG00000019999	KRAS	100	99.471	Ovis_aries
ENSG00000133703	KRAS	100	100.000	ENSPPAG00000038418	KRAS	100	100.000	Pan_paniscus
ENSG00000133703	KRAS	100	100.000	ENSPPRG00000007389	KRAS	100	99.468	Panthera_pardus
ENSG00000133703	KRAS	100	100.000	ENSPTIG00000012574	KRAS	100	99.468	Panthera_tigris_altaica
ENSG00000133703	KRAS	100	100.000	ENSPTRG00000004775	KRAS	100	100.000	Pan_troglodytes
ENSG00000133703	KRAS	100	100.000	ENSPANG00000013197	KRAS	100	100.000	Papio_anubis
ENSG00000133703	KRAS	100	96.296	ENSPKIG00000019449	KRAS	100	96.296	Paramormyrops_kingsleyae
ENSG00000133703	KRAS	100	95.213	ENSPKIG00000025491	-	100	95.213	Paramormyrops_kingsleyae
ENSG00000133703	KRAS	100	100.000	ENSPSIG00000015077	-	100	98.413	Pelodiscus_sinensis
ENSG00000133703	KRAS	99	95.187	ENSPMGG00000013714	KRAS	67	95.187	Periophthalmus_magnuspinnatus
ENSG00000133703	KRAS	89	91.765	ENSPCIG00000014229	KRAS	95	93.976	Phascolarctos_cinereus
ENSG00000133703	KRAS	100	96.825	ENSPFOG00000015499	kras	100	96.825	Poecilia_formosa
ENSG00000133703	KRAS	100	100.000	ENSPLAG00000009352	KRAS	100	98.404	Poecilia_latipinna
ENSG00000133703	KRAS	100	100.000	ENSPMEG00000019525	KRAS	100	98.404	Poecilia_mexicana
ENSG00000133703	KRAS	100	100.000	ENSPREG00000018287	KRAS	100	98.404	Poecilia_reticulata
ENSG00000133703	KRAS	100	100.000	ENSPPYG00000004369	KRAS	100	100.000	Pongo_abelii
ENSG00000133703	KRAS	100	98.942	ENSPVAG00000013668	KRAS	100	98.942	Pteropus_vampyrus
ENSG00000133703	KRAS	100	100.000	ENSPNYG00000013814	KRAS	100	98.936	Pundamilia_nyererei
ENSG00000133703	KRAS	100	100.000	ENSPNAG00000028629	kras	98	98.404	Pygocentrus_nattereri
ENSG00000133703	KRAS	100	100.000	ENSRNOG00000009338	Kras	100	98.942	Rattus_norvegicus
ENSG00000133703	KRAS	100	100.000	ENSRBIG00000037160	KRAS	100	100.000	Rhinopithecus_bieti
ENSG00000133703	KRAS	100	100.000	ENSRROG00000040068	KRAS	100	100.000	Rhinopithecus_roxellana
ENSG00000133703	KRAS	100	100.000	ENSSBOG00000022477	KRAS	100	100.000	Saimiri_boliviensis_boliviensis
ENSG00000133703	KRAS	100	100.000	ENSSHAG00000006631	KRAS	95	98.936	Sarcophilus_harrisii
ENSG00000133703	KRAS	100	96.277	ENSSFOG00015006846	-	100	96.277	Scleropages_formosus
ENSG00000133703	KRAS	100	100.000	ENSSFOG00015023903	KRAS	100	97.872	Scleropages_formosus
ENSG00000133703	KRAS	100	97.872	ENSSMAG00000007370	kras	100	97.872	Scophthalmus_maximus
ENSG00000133703	KRAS	100	100.000	ENSSDUG00000017779	kras	100	98.404	Seriola_dumerili
ENSG00000133703	KRAS	100	100.000	ENSSLDG00000022168	kras	100	98.404	Seriola_lalandi_dorsalis
ENSG00000133703	KRAS	76	97.222	ENSSARG00000007956	KRAS	100	97.222	Sorex_araneus
ENSG00000133703	KRAS	86	100.000	ENSSPUG00000003341	-	100	83.598	Sphenodon_punctatus
ENSG00000133703	KRAS	100	100.000	ENSSPUG00000018789	-	100	99.468	Sphenodon_punctatus
ENSG00000133703	KRAS	100	100.000	ENSSPAG00000009928	kras	100	98.404	Stegastes_partitus
ENSG00000133703	KRAS	100	100.000	ENSSSCG00000026969	KRAS	100	100.000	Sus_scrofa
ENSG00000133703	KRAS	100	100.000	ENSTGUG00000012235	KRAS	100	98.936	Taeniopygia_guttata
ENSG00000133703	KRAS	100	100.000	ENSTRUG00000023449	kras	100	98.404	Takifugu_rubripes
ENSG00000133703	KRAS	100	100.000	ENSTNIG00000012154	kras	100	96.296	Tetraodon_nigroviridis
ENSG00000133703	KRAS	100	99.471	ENSTTRG00000012599	KRAS	100	99.471	Tursiops_truncatus
ENSG00000133703	KRAS	100	100.000	ENSUAMG00000016388	KRAS	100	99.468	Ursus_americanus
ENSG00000133703	KRAS	100	100.000	ENSUMAG00000003274	KRAS	100	99.468	Ursus_maritimus
ENSG00000133703	KRAS	100	98.942	ENSVPAG00000000319	KRAS	100	98.942	Vicugna_pacos
ENSG00000133703	KRAS	100	98.404	ENSXETG00000014935	ralb	100	98.404	Xenopus_tropicalis
ENSG00000133703	KRAS	86	100.000	ENSXETG00000003398	kras	100	87.302	Xenopus_tropicalis
ENSG00000133703	KRAS	100	96.296	ENSXCOG00000020508	kras	100	96.296	Xiphophorus_couchianus
ENSG00000133703	KRAS	100	100.000	ENSXMAG00000025790	kras	100	97.872	Xiphophorus_maculatus

Gene Ontology

Go ID	Go_term	PubmedID	Evidence	Category
GO:0000165	MAPK cascade	-	TAS	Process
GO:0001889	liver development	-	IEA	Process
GO:0001934	positive regulation of protein phosphorylation	22065586.	IMP	Process
GO:0002223	stimulatory C-type lectin receptor signaling pathway	-	TAS	Process
GO:0003924	GTPase activity	-	IEA	Function
GO:0005515	protein binding	12732644.25416956.	IPI	Function
GO:0005525	GTP binding	-	IEA	Function
GO:0005737	cytoplasm	23698361.	IDA	Component
GO:0005739	mitochondrion	-	IEA	Component
GO:0005829	cytosol	-	IEA	Component
GO:0005886	plasma membrane	-	TAS	Component
GO:0005925	focal adhesion	21423176.	HDA	Component
GO:0007265	Ras protein signal transduction	-	TAS	Process
GO:0007565	female pregnancy	-	IEA	Process
GO:0008284	positive regulation of cell proliferation	23698361.	IMP	Process
GO:0008542	visual learning	-	IEA	Process
GO:0010628	positive regulation of gene expression	22065586.	IMP	Process
GO:0016020	membrane	19946888.	HDA	Component
GO:0019002	GMP binding	-	IEA	Function
GO:0019003	GDP binding	-	IEA	Function
GO:0019221	cytokine-mediated signaling pathway	-	IEA	Process
GO:0021897	forebrain astrocyte development	-	IEA	Process
GO:0030036	actin cytoskeleton organization	-	IEA	Process
GO:0030275	LRR domain binding	-	IEA	Function
GO:0031234	extrinsic component of cytoplasmic side of plasma membrane	23698361.	IDA	Component
GO:0031647	regulation of protein stability	24623306.	IMP	Process
GO:0032228	regulation of synaptic transmission, GABAergic	-	IEA	Process
GO:0035022	positive regulation of Rac protein signal transduction	-	IEA	Process
GO:0035900	response to isolation stress	-	IEA	Process
GO:0038002	endocrine signaling	-	IEA	Process
GO:0043406	positive regulation of MAP kinase activity	-	IEA	Process
GO:0043524	negative regulation of neuron apoptotic process	-	IEA	Process
GO:0044877	protein-containing complex binding	23209302.	IDA	Function
GO:0045121	membrane raft	-	IEA	Component
GO:0045596	negative regulation of cell differentiation	-	IEA	Process
GO:0048169	regulation of long-term neuronal synaptic plasticity	-	IEA	Process
GO:0048873	homeostasis of number of cells within a tissue	-	IEA	Process
GO:0051000	positive regulation of nitric-oxide synthase activity	-	IEA	Process
GO:0051092	positive regulation of NF-kappaB transcription factor activity	-	IEA	Process
GO:0051146	striated muscle cell differentiation	-	IEA	Process
GO:0051384	response to glucocorticoid	-	IEA	Process
GO:0051385	response to mineralocorticoid	-	IEA	Process
GO:0060441	epithelial tube branching involved in lung morphogenesis	-	IEA	Process
GO:2000774	positive regulation of cellular senescence	-	IEA	Process

Cancer associated literatures

PID	Title	Article	Time	Author	Doi
21573767	Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy.	Int J Colorectal Dis	2011 Oct	Oltedal S	doi: 10.1007/s00384-011-1233-5
21884745	Tumor-infiltrating lymphocytes and dendritic cells in human colorectal cancer: their relationship to KRAS mutational status and disease recurrence.	Hum Immunol	2011 Nov	Kocian P	doi: 10.1016/j.humimm.2011.07.312
26631045	MicroRNA-613 inhibited ovarian cancer cell proliferation and invasion by regulating KRAS.	Tumour Biol	2016 May	Fu X	doi: 10.1007/s13277-015-4507-7
26252055	Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer.	Cancer Biol Ther	2015	Buim ME	doi: 10.1080/15384047.2015.1070991
26959608	Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation.	Cell Cycle	2016	Lochhead PA	doi: 10.1080/15384101.2015.1120915.
27857191	Deregulation of the miR-16-KRAS axis promotes colorectal cancer.	Sci Rep	2016 Nov 18	You C	doi: 10.1038/srep37459.
30809081	Relationships among KRAS mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer.	World J Gastroenterol	2019 Feb 21	Wan XB	doi: 10.3748/wjg.v25.i7.808.
29282362	Genetic variants in the VEGF pathway as prognostic factors in stages II and III colon cancer.	Pharmacogenomics J	2018 Jul	Riera P	doi: 10.1038/s41397-017-0009-x
22198706	The complex intratumoral heterogeneity of colon cancer highlighted by laser microdissection.	Dig Dis Sci	2012 May	Buob D	doi: 10.1007/s10620-011-2023-1
18549880	Oncogenic KRAS induces progenitor cell expansion and malignant transformation in zebrafish exocrine pancreas.	Gastroenterology	2008 Jun	Park SW	doi: 10.1053/j.gastro.2008.02.084
20628283	Alcohol consumption and rectal tumor mutations and epigenetic changes.	Dis Colon Rectum	2010 Aug	Slattery ML	doi: 10.1007/DCR.0b013e3181d325db.
12606951	LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer.	Oncogene	2003 Feb 27	Li J	-
25809746	Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer.	J Thromb Haemost	2015 Jun	Ades S	doi: 10.1111/jth.12910
24200637	Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.	Cancer Genet	2013 Sep-Oct	Jiang L	doi: 10.1016/j.cancergen.2013.09.004
26352110	KRAS, NRAS, BRAF mutations and high counts of poorly differentiated clusters of neoplastic cells in colorectal cancer: observational analysis of 175 cases.	Pathology	2015 Oct	Barresi V	doi: 10.1097/PAT.0000000000000300.
22971512	Detection of KRAS mutations and their associations with clinicopathological features and survival in Chinese colorectal cancer patients.	J Int Med Res	2012	Li Z	-
25491325	KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.	J Exp Clin Cancer Res	2014 Dec 10	Xu JM	doi: 10.1186/s13046-014-0104-7.
20570890	Genomic and biological characterization of exon 4 KRAS mutations in human cancer.	Cancer Res	2010 Jul 15	Janakiraman M	doi: 10.1158/0008-5472.CAN-10-0192
23240926	Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.	Thyroid	2013 Jan	Ciampi R	doi: 10.1089/thy.2012.0207
21982684	EGFR and KRAS mutations and altered c-Met gene copy numbers in primary non-small cell lung cancer and associated stage N2 lymph node-metastasis.	Cancer Lett	2012 Jan 1	Han CB	doi: 10.1016/j.canlet.2011.09.012
23027861	Interplay between menin and K-Ras in regulating lung adenocarcinoma.	J Biol Chem	2012 Nov 16	Wu Y	doi: 10.1074/jbc.M112.382416
25541062	AZD6244 inhibits cisplatin-induced ERK1/2 activation and potentiates cisplatin-associated cytotoxicity in K-ras G12D preclinical models.	Cancer Lett	2015 Mar 1	Kim EY	doi: 10.1016/j.canlet.2014.12.041
19372139	The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras.	Carcinogenesis	2009 Jun	Tsang WP	doi: 10.1093/carcin/bgp094
25687873	Can Serum be Used for Analyzing the KRAS Mutation Status in Patients with Advanced Colorectal Cancer?	Cancer Res Treat	2015 Oct	Kim ST	doi: 10.4143/crt.2014.106
22876876	Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group.	BMC Cancer	2012 Aug 9	Reinacher-Schick A	doi: 10.1186/1471-2407-12-349.
21807965	Progressive genomic instability in the FVB/Kras(LA2) mouse model of lung cancer.	Mol Cancer Res	2011 Oct	To MD	doi: 10.1158/1541-7786.MCR-11-0219
22049925	Tumor suppressor p16INK4a controls oncogenic K-Ras function in human pancreatic cancer cells.	Cancer Sci	2012 Feb	Rabien A	doi: 10.1111/j.1349-7006.2011.02140.x
26252300	KRAS Mutation Status Is Not a Predictor for Tumor Response and Survival in Rectal Cancer Patients Who Received Preoperative Radiotherapy With 5-Fluoropyrimidine Followed by Curative Surgery.	Medicine (Baltimore)	2015 Aug	Lee JW	doi: 10.1097/MD.0000000000001284.
20098682	Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes.	PLoS One	2010 Jan 21	Lurkin I	doi: 10.1371/journal.pone.0008802.
20682398	Gene methylation of SFRP2, P16, DAPK1, HIC1, and MGMT and KRAS mutations in sporadic colorectal cancer.	Cancer Genet Cytogenet	2010 Sep	Pehlivan S	doi: 10.1016/j.cancergencyto.2010.05.019.
27270901	Comparison of KRAS mutation status between primary tumor and metastasis in Chinese colorectal cancer patients.	Med Oncol	2016 Jul	Li ZZ	doi: 10.1007/s12032-016-0787-z
28025078	Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer.	Hum Pathol	2017 Apr	Reggiani Bonetti L	doi: 10.1016/j.humpath.2016.12.011
27346571	High frequency of KRAS mutation in early onset colorectal adenocarcinoma: implications for pathogenesis.	Hum Pathol	2016 Oct	Watson R	doi: 10.1016/j.humpath.2016.06.010
26616862	Regulation of oncogenic KRAS signaling via a novel KRAS-integrin-linked kinase-hnRNPA1 regulatory loop in human pancreatic cancer cells.	Oncogene	2016 Jul 28	Chu PC	doi: 10.1038/onc.2015.458
26333174	MiR-622 inhibited colorectal cancer occurrence and metastasis by suppressing K-Ras.	Mol Carcinog	2016 Sep	Fang Y	doi: 10.1002/mc.22380
27234640	CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).	Ann Oncol	2016 Aug	Michl M	doi: 10.1093/annonc/mdw222
28468801	ΔNp63α is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis.	Proc Natl Acad Sci U S A	2017 May 16	Hu L	doi: 10.1073/pnas.1617816114
28885658	Circulating tumor DNA is effective for detection of KRAS mutation in colorectal cancer: a meta-analysis.	Int J Biol Markers	2017 Oct 31	Tang M	doi: 10.5301/ijbm.5000295.
30711927	The Role of KRAS in Endometrial Cancer: A Mini-Review.	Anticancer Res	2019 Feb	Sideris M	doi: 10.21873/anticanres.13145.
30611220	Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma.	BMC Cancer	2019 Jan 5	Choi MH	doi: 10.1186/s12885-018-5195-7.
21811765	Correlation between computed tomography findings and epidermal growth factor receptor and KRAS gene mutations in patients with pulmonary adenocarcinoma.	Oncol Rep	2011 Nov	Sugano M	doi: 10.3892/or.2011.1412
27916952	High Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer.	Int J Mol Sci	2016 Dec 1	Jeantet M	-
28665451	Discordance in RAS mutations between primary colon tumor and metastases: a real event or a matter of methodology?	Int J Biol Markers	2017 Oct 31	De Stefano A	doi: 10.5301/ijbm.5000273.
18946061	K-ras mutations and benefit from cetuximab in advanced colorectal cancer.	N Engl J Med	2008 Oct 23	Karapetis CS	doi: 10.1056/NEJMoa0804385.
16091732	Dual effect of Kras(D12) knockdown on tumorigenesis: increased immune-mediated tumor clearance and abrogation of tumor malignancy.	Oncogene	2005 Dec 15	Smakman N	-
27630331	Prediction of KRAS Mutation in Rectal Cancer Using MRI.	Anticancer Res	2016 Sep	Shin YR	-
23242173	KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance.	Virchows Arch	2013 Jan	Dijkstra JR	doi: 10.1007/s00428-012-1356-2
24152947	Pancreatic cancer: modulation of KRAS, MicroRNAs, and intercellular communication in the setting of tumor heterogeneity.	Pancreas	2013 Nov	Lou E	doi: 10.1097/MPA.0000000000000007.
23157823	[Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases].	Zhonghua Bing Li Xue Za Zhi	2012 Sep	Gao J	doi: 10.3760/cma.j.issn.0529-5807.2012.09.002.
23528430	Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology.	Exp Mol Pathol	2013 Aug	Perez K	doi: 10.1016/j.yexmp.2013.01.004
17592266	The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.	Am J Surg Pathol	2007 Jul	Dehari R	-
23157828	[Correlation of KRAS gene mutations and clinicopathologic parameters in colorectal carcinoma].	Zhonghua Bing Li Xue Za Zhi	2012 Sep	Wang Q	doi: 10.3760/cma.j.issn.0529-5807.2012.09.007.
28468669	KRAS mutation analysis of single circulating tumor cells from patients with metastatic colorectal cancer.	BMC Cancer	2017 May 3	Kondo Y	doi: 10.1186/s12885-017-3305-6.
27863403	Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.	Oncotarget	2016 Dec 20	Kidess-Sigal E	doi: 10.18632/oncotarget.13350.
29445180	Myeloid-derived interleukin-1β drives oncogenic KRAS-NF-κΒ addiction in malignant pleural effusion.	Nat Commun	2018 Feb 14	Marazioti A	doi: 10.1038/s41467-018-03051-z.
29315556	KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK-ERK pathway in pancreatic cancer.	Int J Cancer	2018 Jun 1	Yang K	doi: 10.1002/ijc.31248
29027536	KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome.	Mod Pathol	2018 Feb	Zuo T	doi: 10.1038/modpathol.2017.121
30917791	Impact of primary colorectal Cancer location on the KRAS status and its prognostic value.	BMC Gastroenterol	2019 Mar 27	Xie MZ	doi: 10.1186/s12876-019-0965-5.
16482519	Genetic and epigenetic alterations in lung tumors from bitransgenic Ki-rasG12C expressing mice.	Mol Carcinog	2006 Jul	Floyd HS	-
20627194	Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer.	Transl Res	2010 Aug	Yokota T	doi: 10.1016/j.trsl.2010.05.007
25023700	MutT Homolog 1 (MTH1) maintains multiple KRAS-driven pro-malignant pathways.	Oncogene	2015 May 14	Patel A	doi: 10.1038/onc.2014.195
16257181	Oncogenic K-Ras down-regulates Rac1 and RhoA activity and enhances migration and invasion of pancreatic carcinoma cells through activation of p38.	Cell Signal	2006 Aug	Dreissigacker U	-
26868125	Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation.	BMC Cancer	2016 Feb 11	Cavalloni G	doi: 10.1186/s12885-016-2136-1.
24440911	Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma.	Cell Death Differ	2014 May	Zhang Y	doi: 10.1038/cdd.2013.196
26393682	The association between let-7, RAS and HIF-1α in Ewing Sarcoma tumor growth.	Oncotarget	2015 Oct 20	Hameiri-Grossman M	doi: 10.18632/oncotarget.5616.
24139215	The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome.	Hum Pathol	2013 Dec	Robertson S	doi: 10.1016/j.humpath.2013.07.026
22761399	Label-free quantitative proteomics and N-glycoproteomics analysis of KRAS-activated human bronchial epithelial cells.	Mol Cell Proteomics	2012 Oct	Sudhir PR	-
22927534	Hurdles and complexities of codon 13 KRAS mutations.	J Clin Oncol	2012 Oct 10	Morelli MP	doi: 10.1200/JCO.2012.43.6535
17638924	RAS/ERK modulates TGFbeta-regulated PTEN expression in human pancreatic adenocarcinoma cells.	Carcinogenesis	2007 Nov	Chow JY	-
23619604	KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma.	Mod Pathol	2013 Oct	Rekhtman N	doi: 10.1038/modpathol.2013.74
23112547	MUC5AC/β-catenin expression and KRAS gene alteration in laterally spreading colorectal tumors.	World J Gastroenterol	2012 Oct 21	Nakae K	doi: 10.3748/wjg.v18.i39.5551.
19960433	Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancer.	Int J Cancer	2010 Aug 1	Dobrzycka B	doi: 10.1002/ijc.25077.
12082617	Common occurrence of multiple K-RAS mutations in pancreatic cancers with associated precursor lesions and in biliary cancers.	Oncogene	2002 Jun 20	Laghi L	-
18834226	CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels.	Arch Pathol Lab Med	2008 Oct	Lee S	doi: 10.1043/1543-2165(2008)132[1657:CIMPIC]2.0.CO;2.
24742923	Mapping of actionable mutations to histological subtype domains in lung adenocarcinoma: implications for precision medicine.	Oncotarget	2014 Apr 30	Wright GM	-
24947996	Targeting the K-Ras--JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation.	Oncotarget	2014 Jul 15	Okada M	-
19789336	RAS mutations affect tumor necrosis factor-induced apoptosis in colon carcinoma cells via ERK-modulatory negative and positive feedback circuits along with non-ERK pathway effects.	Cancer Res	2009 Oct 15	Kreeger PK	doi: 10.1158/0008-5472.CAN-09-1921
23887305	The pathogenesis of atypical proliferative Brenner tumor: an immunohistochemical and molecular genetic analysis.	Mod Pathol	2014 Feb	Kuhn E	doi: 10.1038/modpathol.2013.142
19893451	Resequencing analysis of the human tyrosine kinase gene family in pancreatic cancer.	Pancreas	2009 Oct	Kubo T	doi: 10.1097/MPA.0b013e3181b8feb0.
22138963	Is KRAS mutation associated with interval colorectal cancers?	Dig Dis Sci	2012 Apr	Shaukat A	doi: 10.1007/s10620-011-1974-6
18833187	[K-ras mutations detection in paraaortic lymph nodes and its prognostic value after the surgical treatment of pancreas cancer].	Khirurgiia (Mosk)	2008	Agaev BA	-
25013125	Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002.	Clin Cancer Res	2014 Sep 1	Couraud S	doi: 10.1158/1078-0432.CCR-13-3063
16760301	Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study.	Ann Oncol	2006 Jun	Bazan V	-
24496383	Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA delivery.	Mol Ther	2014 May	Mao CQ	doi: 10.1038/mt.2014.18
12651912	Met receptor overexpression and oncogenic Ki-ras mutation cooperate to enhance tumorigenicity of colon cancer cells in vivo.	Mol Cancer Res	2003 Mar	Long IS	-
20675343	The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS.	Carcinogenesis	2010 Oct	Zhao WG	doi: 10.1093/carcin/bgq160
18432074	[K-ras mutation as a prognostic factor in colorectal carcinoma].	Rozhl Chir	2008 Jan	Sacha M	-
25811077	miR-134 functions as a tumor suppressor in cell proliferation and epithelial-to-mesenchymal Transition by targeting KRAS in renal cell carcinoma cells.	DNA Cell Biol	2015 Jun	Liu Y	doi: 10.1089/dna.2014.2629
19888477	Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics.	PLoS One	2009 Nov 4	Kotoula V	doi: 10.1371/journal.pone.0007746.
24263065	KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer.	Br J Cancer	2013 Dec 10	Spindler KG	doi: 10.1038/bjc.2013.633
17707462	High-degree tumor budding and podia-formation in sporadic colorectal carcinomas with K-ras gene mutations.	Hum Pathol	2007 Nov	Prall F	-
26677873	Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy.	Proc Natl Acad Sci U S A	2016 Jan 5	Eng CH	doi: 10.1073/pnas.1515617113
17659731	Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer.	World J Gastroenterol	2007 Jul 21	Salek C	-
21335545	Protein kinase C δ is a downstream effector of oncogenic K-ras in lung tumors.	Cancer Res	2011 Mar 15	Symonds JM	doi: 10.1158/0008-5472.CAN-10-1511
21873159	Oncogenic KRAS regulates miR-200c and miR-221/222 in a 3D-specific manner in colorectal cancer cells.	Anticancer Res	2011 Jul	Tsunoda T	-
23729268	KRAS gene mutations in correlation with clinicopathological features of colorectal carcinomas in Indian patient cohort.	Med Oncol	2013	Patil H	doi: 10.1007/s12032-013-0617-5
26452035	Deletion of cyclooxygenase-2 inhibits K-ras-induced lung carcinogenesis.	Oncotarget	2015 Nov 17	Pan Y	doi: 10.18632/oncotarget.5558.
26267534	Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.	Cancer Cell	2015 Aug 10	Herrero A	doi: 10.1016/j.ccell.2015.07.001.
24598028	The inflammatory cytokine TNFα cooperates with Ras in elevating metastasis and turns WT-Ras to a tumor-promoting entity in MCF-7 cells.	BMC Cancer	2014 Mar 6	Leibovich-Rivkin T	doi: 10.1186/1471-2407-14-158.
25137394	KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer.	PLoS One	2014 Aug 19	Kalikaki A	doi: 10.1371/journal.pone.0104902
22441881	Clinical significance of KRAS gene mutation and epidermal growth factor receptor expression in Japanese patients with squamous cell carcinoma of the larynx, oropharynx and hypopharynx.	Int J Clin Oncol	2013 Jun	Fujii S	doi: 10.1007/s10147-012-0402-z
25946211	Comparison of genetic and epigenetic alterations of primary tumors and matched plasma samples in patients with colorectal cancer.	PLoS One	2015 May 6	Danese E	doi: 10.1371/journal.pone.0126417
23157826	[Correlation between KRAS mutations and clinicopathologic features in colorectal carcinomas].	Zhonghua Bing Li Xue Za Zhi	2012 Sep	Gao J	doi: 10.3760/cma.j.issn.0529-5807.2012.09.005.
16575407	Activation of Ras/Raf protects cells from melanoma differentiation-associated gene-5-induced apoptosis.	Cell Death Differ	2006 Nov	Lin L	-
22589270	A comprehensive survey of Ras mutations in cancer.	Cancer Res	2012 May 15	Prior IA	doi: 10.1158/0008-5472.CAN-11-2612.
24998492	Adenoma and carcinoma components in colonic tumors show discordance for KRAS mutation.	Hum Pathol	2014 Sep	Hershkovitz D	doi: 10.1016/j.humpath.2014.05.005
21408138	Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR.	PLoS One	2011 Mar 8	van Eijk R	doi: 10.1371/journal.pone.0017791.
20512148	DYRK1B-dependent autocrine-to-paracrine shift of Hedgehog signaling by mutant RAS.	Nat Struct Mol Biol	2010 Jun	Lauth M	doi: 10.1038/nsmb.1833
22588152	A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer.	J Thorac Oncol	2012 Jun	Cuffe S	doi: 10.1097/JTO.0b013e31824fe9e6.
20565773	SMAD4--molecular gladiator of the TGF-beta signaling is trampled upon by mutational insufficiency in colorectal carcinoma of Kashmiri population: an analysis with relation to KRAS proto-oncogene.	BMC Cancer	2010 Jun 17	Sameer AS	doi: 10.1186/1471-2407-10-300.
25133424	Menin determines K-RAS proliferative outputs in endocrine cells.	J Clin Invest	2014 Sep	Chamberlain CE	doi: 10.1172/JCI69004
19995707	Mutations in the KRAS gene in ovarian tumors.	Folia Histochem Cytobiol	2009	Dobrzycka B	doi: 10.2478/v10042-009-0039-6.
25798815	Expression of KRASG12V in Zebrafish Gills Induces Hyperplasia and CXCL8-Associated Inflammation.	Zebrafish	2015 Jun	Shive HR	doi: 10.1089/zeb.2014.1038
19101897	Mutations of RAS gene family in specimens of bladder cancer.	Urol J	2008 Fall	Karimianpour N	-
22247021	Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.	J Natl Cancer Inst	2012 Feb 8	Ihle NT	doi: 10.1093/jnci/djr523
21055216	[K-ras gene mutation in colorectal cancer and its clinicopathologic significance].	Zhonghua Wai Ke Za Zhi	2010 Aug 15	Yuan Y	-
22222375	RAS oncogenic signal upregulates EZH2 in pancreatic cancer.	Biochem Biophys Res Commun	2012 Jan 20	Fujii S	doi: 10.1016/j.bbrc.2011.12.099
26560143	Absolute Quantification of Endogenous Ras Isoform Abundance.	PLoS One	2015 Nov 11	Mageean CJ	doi: 10.1371/journal.pone.0142674
21825899	Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer.	Dis Colon Rectum	2011 Sep	Watanabe T	doi: 10.1097/DCR.0b013e31821d37a3.
22706026	Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression.	J Mol Biol	2012 Sep 28	Spangler JB	doi: 10.1016/j.jmb.2012.06.014
22708448	[Age-related and clinical-pathogenetic features of colorectal cancer associated with status of K-ras gene].	Adv Gerontol	2012	Beliaeva AV	-
27062566	KRAS mutation associated with CD44/CD166 immunoexpression as predictors of worse outcome in metastatic colon cancer.	Cancer Biomark	2016 Mar 4	Ribeiro KB	doi: 10.3233/CBM-160592.
26902163	Variation in KRAS driver substitution distributions between tumor types is determined by both mutation and natural selection.	Sci Rep	2016 Feb 23	Ostrow SL	doi: 10.1038/srep21927.
21332555	Analysis of K-ras, BRAF, and PIK3CA mutations in laterally-spreading tumors of the colorectum.	J Gastroenterol Hepatol	2011 Mar	Kaji E	doi: 10.1111/j.1440-1746.2010.06485.x.
24368337	The proto-oncogene KRAS is targeted by miR-200c.	Oncotarget	2014 Jan 15	Kopp F	-
22427190	Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma.	Int J Biol Markers	2012 Jan-Mar	Bagadi SB	doi: 10.5301/JBM.2012.9108.
26837759	Activated KRAS Cooperates with MLL-AF4 to Promote Extramedullary Engraftment and Migration of Cord Blood CD34+ HSPC But Is Insufficient to Initiate Leukemia.	Cancer Res	2016 Apr 15	Prieto C	doi: 10.1158/0008-5472.CAN-15-2769
25341034	RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer.	Cell Death Dis	2014 Oct 23	Kang R	doi: 10.1038/cddis.2014.445.
26684859	Alterations in Tumor DNA Are Related to Short Postoperative Survival in Patients Resected for Pancreatic Carcinoma Aimed at Cure.	Pancreas	2016 Jul	Asting AG	doi: 10.1097/MPA.0000000000000566.
27345584	Targeting the serrated pathway of colorectal cancer with mutation in BRAF.	Biochim Biophys Acta	2016 Aug	Matos P	doi: 10.1016/j.bbcan.2016.06.003
27550813	Suppression of MicroRNA 200 Family Expression by Oncogenic KRAS Activation Promotes Cell Survival and Epithelial-Mesenchymal Transition in KRAS-Driven Cancer.	Mol Cell Biol	2016 Oct 13	Zhong X	doi: 10.1128/MCB.00079-16
26279302	Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer.	Oncogene	2016 May 12	Zhang S	doi: 10.1038/onc.2015.306
27041569	AMPK promotes tolerance to Ras pathway inhibition by activating autophagy.	Oncogene	2016 Oct 6	Sanduja S	doi: 10.1038/onc.2016.70
28697193	The value of 18FDG PET/CT parameters, hematological parameters and tumor markers in predicting KRAS oncogene mutation in colorectal cancer.	Hell J Nucl Med	2017 May-Aug	Oner AO	doi: 10.1967/s002449910557
28188750	KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.	Hum Pathol	2017 Jul	Jang S	doi: 10.1016/j.humpath.2017.01.010
28619714	The G protein-coupled receptor GPR31 promotes membrane association of KRAS.	J Cell Biol	2017 Aug 7	Fehrenbacher N	doi: 10.1083/jcb.201609096
28699162	Spatial distribution of EGFR and KRAS mutation frequencies correlates with histological growth patterns of lung adenocarcinomas.	Int J Cancer	2017 Nov 1	Dietz S	doi: 10.1002/ijc.30881
28867179	RAGE maintains high levels of NFκB and oncogenic Kras activity in pancreatic cancer.	Biochem Biophys Res Commun	2017 Nov 4	Azizan N	doi: 10.1016/j.bbrc.2017.08.147
28188683	Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors.	Mol Oncol	2017 Apr	Polosukhina D	doi: 10.1002/1878-0261.12044
29175303	EGFR, KRAS, BRAF and HER2 testing in metastatic lung adenocarcinoma: Value of testing on samples with poor specimen adequacy and analysis of discrepancies.	Exp Mol Pathol	2017 Dec	Forest F	doi: 10.1016/j.yexmp.2017.11.013
27382031	Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer.	Oncologist	2016 Aug	Moretto R	doi: 10.1634/theoncologist.2016-0084
29246442	Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA.	Immunity	2017 Dec 19	Coelho MA	doi: 10.1016/j.immuni.2017.11.016
27447549	Oncogenic Ras triggers hyperproliferation and impairs polarized colonic morphogenesis by autocrine ErbB3 signaling.	Oncotarget	2016 Aug 16	Muller Y	doi: 10.18632/oncotarget.10658.
27888800	Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms.	Oncotarget	2016 Dec 13	Lee YJ	doi: 10.18632/oncotarget.13449.
27999210	LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.	Oncotarget	2017 Feb 7	Vakana E	doi: 10.18632/oncotarget.14002.
28096270	Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers.	Clin Cancer Res	2017 Jul 15	Fujii T	doi: 10.1158/1078-0432.CCR-16-2592
29203670	Kras mutant genetically engineered mouse models of human cancers are genomically heterogeneous.	Proc Natl Acad Sci U S A	2017 Dec 19	Chung WJ	doi: 10.1073/pnas.1708391114
28708207	Variations in transrenal DNA and comparison with plasma DNA as a diagnostic marker for colorectal cancer.	Int J Biol Markers	2017 Oct 31	Tian F	doi: 10.5301/ijbm.5000288.
29115540	MicroRNA-326 inhibits melanoma progression by targeting KRAS and suppressing the AKT and ERK signalling pathways.	Oncol Rep	2018 Jan	Kang K	doi: 10.3892/or.2017.6074
29103773	KRAS mutation and immunohistochemical profile in intraductal papillary neoplasm of the intrahepatic bile ducts.	Pathol Res Pract	2018 Jan	Xian ZH	doi: 10.1016/j.prp.2017.10.017
30013058	In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer.	Nat Commun	2018 Jul 16	Grzeskowiak CL	doi: 10.1038/s41467-018-04572-3.
29104111	Clinical and biological significance of miR-193a-3p targeted KRAS in colorectal cancer pathogenesis.	Hum Pathol	2018 Jan	Mamoori A	doi: 10.1016/j.humpath.2017.10.024
29358307	miR-422a inhibits osteosarcoma proliferation by targeting BCL2L2 and KRAS.	Biosci Rep	2018 Mar 21	Zhang H	doi: 10.1042/BSR20170339
29240583	Site-specific Differences in Colonic Adenocarcinoma: KRAS Mutations and High Tumor Budding Are More Frequent in Cecal Adenocarcinoma.	Am J Surg Pathol	2018 Mar	Landau MA	doi: 10.1097/PAS.0000000000001004.
22833420	Epidermal growth factor receptor and Kras gene expression: reliability of mutational analysis on cytological samples.	Diagn Cytopathol	2013 Jul	Bozzetti C	doi: 10.1002/dc.22905
26722374	Glycoproteomic Approach Identifies KRAS as a Positive Regulator of CREG1 in Non-small Cell Lung Cancer Cells.	Theranostics	2016 Jan 1	Clark DJ	doi: 10.7150/thno.12350
27461636	rs61764370 polymorphism of Kras and risk of cancer in Caucasian population: A meta-analysis.	J Cancer Res Ther	2016 Apr-Jun	Zhang SY	doi: 10.4103/0973-1482.147379.
25633745	Activation of KRAS promotes the mesenchymal features of basal-type breast cancer.	Exp Mol Med	2015 Jan 30	Kim RK	doi: 10.1038/emm.2014.99.
24861525	Genetic analysis in APC, KRAS, and TP53 in patients with stomach and colon cancer.	Rev Gastroenterol Mex	2014 Apr-Jun	Palacio-Rua KA	doi: 10.1016/j.rgmx.2014.05.001
23558076	Decreased expression of DAB2IP in pancreatic cancer with wild-type KRAS.	Hepatobiliary Pancreat Dis Int	2013 Apr	Duan YF	-
24467518	Cetuximab inhibits gastric cancer growth in vivo, independent of KRAS status.	Curr Cancer Drug Targets	2014	Shi M	-
26376292	Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.	Int J Cancer	2016 Mar 1	de Cuba EM	doi: 10.1002/ijc.29855
24259266	KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer.	Int J Cancer	2014 Jun 15	Kohonen-Corish MR	doi: 10.1002/ijc.28619
21385923	The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.	Clin Cancer Res	2011 Jun 1	Pharoah PD	doi: 10.1158/1078-0432.CCR-10-3405
24331409	KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.	Lung Cancer	2014 Feb	Maus MK	doi: 10.1016/j.lungcan.2013.11.010
27096769	K-ras gene mutation as an early prognostic marker of colon cancer.	Pol Przegl Chir	2016 Jan 1	Szpon	doi: 10.1515/pjs-2016-0021.
24694877	Embelin suppresses growth of human pancreatic cancer xenografts, and pancreatic cancer cells isolated from KrasG12D mice by inhibiting Akt and Sonic hedgehog pathways.	PLoS One	2014 Apr 2	Huang M	doi: 10.1371/journal.pone.0092161
14761400	[Co-detection of P21, P53 and HSP70 and their possible role in diagnosis of polycyclic aromatic hydrocarbons (PAHs)-related lung cancer].	Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi	2003 Oct	Lu QF	-
25158139	Clinical and metabolic parameters in non-small cell lung carcinoma and colorectal cancer patients with and without KRAS mutations.	Int J Environ Res Public Health	2014 Aug 25	Yilmaz A	doi: 10.3390/ijerph110908645.
25002494	Ras transformation uncouples the kinesin-coordinated cellular nutrient response.	Proc Natl Acad Sci U S A	2014 Jul 22	Zaganjor E	doi: 10.1073/pnas.1411016111
25713893	Impact of KRAS mutation on outcome of patients with metastatic colorectal cancer.	Hepatogastroenterology	2014 Oct	Chang YY	-
24021343	p16INK4A, p53, EGFR expression and KRAS mutation status in squamous cell cancers of the anus: correlation with outcomes following chemo-radiotherapy.	Radiother Oncol	2013 Oct	Gilbert DC	doi: 10.1016/j.radonc.2013.08.002
25450872	Outcomes by tumor histology and KRAS mutation status after lung stereotactic body radiation therapy for early-stage non-small-cell lung cancer.	Clin Lung Cancer	2015 Jan	Mak RH	doi: 10.1016/j.cllc.2014.09.005
25137136	Integrating multi-omics for uncovering the architecture of cross-talking pathways in breast cancer.	PLoS One	2014 Aug 19	Wang L	doi: 10.1371/journal.pone.0104282
24394008	[Analysis of KRAS status in cancer tissue with submucosal or deeper invasion in patients with familial adenomatous polyposis].	Gan To Kagaku Ryoho	2013 Nov	Tajima Y	-
27573925	Low mutation percentage of KRAS and BRAF genes in Brazilian anal tumors.	Mol Med Rep	2016 Oct	Bidinotto LT	doi: 10.3892/mmr.2016.5684
28259994	Overexpression of wild-type p21Ras plays a prominent role in colorectal cancer.	Int J Mol Med	2017 Apr	Bai S	doi: 10.3892/ijmm.2017.2903
27182622	KRAS and TP53 mutations in bronchoscopy samples from former lung cancer patients.	Mol Carcinog	2017 Feb	Gao W	doi: 10.1002/mc.22501
27312358	The effect of forced expression of mutated K-RAS gene on gastrointestinal cancer cell lines and the IGF-1R targeting therapy.	Mol Carcinog	2017 Feb	Matsunaga Y	doi: 10.1002/mc.22513
28139399	Utility of serum DNA as a marker for KRAS mutations in pancreatic cancer tissue.	Pancreatology	2017 Mar - Apr	Ako S	doi: 10.1016/j.pan.2016.12.011
28710768	Panobinostat sensitizes KRAS-mutant non-small-cell lung cancer to gefitinib by targeting TAZ.	Int J Cancer	2017 Nov 1	Lee WY	doi: 10.1002/ijc.30888
27477280	Fatty Acid Oxidation Mediated by Acyl-CoA Synthetase Long Chain 3 Is Required for Mutant KRAS Lung Tumorigenesis.	Cell Rep	2016 Aug 9	Padanad MS	doi: 10.1016/j.celrep.2016.07.009
28475173	MicroRNA-30a attenuates mutant KRAS-driven colorectal tumorigenesis via direct suppression of ME1.	Cell Death Differ	2017 Jul	Shen H	doi: 10.1038/cdd.2017.63
29246726	K-ras mutation promotes ionizing radiation-induced invasion and migration of lung cancer in part via the Cathepsin L/CUX1 pathway.	Exp Cell Res	2018 Jan 15	Wang L	doi: 10.1016/j.yexcr.2017.12.006
30018674	Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer.	Dis Markers	2018 Jun 19	Reggiani Bonetti L	doi: 10.1155/2018/2959801
30171261	mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer.	Oncogene	2019 Jan	Liang SQ	doi: 10.1038/s41388-018-0479-6
30394984	A Changing Spectrum of Colorectal Cancer Biology With Age: Implications for the Young Patient.	Dis Colon Rectum	2019 Jan	Chouhan H	doi: 10.1097/DCR.0000000000001188.
21645454	[Study on point mutations of K-ras gene in non-small cell lung cancer in Guangxi].	Zhongguo Fei Ai Za Zhi	2011 Jun	Zhong W	doi: 10.3779/j.issn.1009-3419.2011.06.06.
20619739	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.	Lancet Oncol	2010 Aug	De Roock W	doi: 10.1016/S1470-2045(10)70130-3
22337533	Postmenopausal hormone therapy and colorectal cancer risk in relation to somatic KRAS mutation status among older women.	Cancer Epidemiol Biomarkers Prev	2012 Apr	Limburg PJ	doi: 10.1158/1055-9965.EPI-11-1168
14601056	Loss of heterozygosity of chromosome 12p does not correlate with KRAS mutation in non-small cell lung cancer.	Int J Cancer	2003 Dec 20	Uchiyama M	-
23134218	MicroRNA let-7a inhibits the proliferation and invasion of nonsmall cell lung cancer cell line 95D by regulating K-Ras and HMGA2 gene expression.	Cancer Biother Radiopharm	2013 Mar	Wang YY	doi: 10.1089/cbr.2012.1307
26575954	Catabolic pathways regulated by mTORC1 are pivotal for survival and growth of cancer cells expressing mutant Ras.	Oncotarget	2015 Dec 1	Sung S	doi: 10.18632/oncotarget.6334.
23075074	Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review.	Cancer Invest	2012 Dec	Han CB	doi: 10.3109/07357907.2012.732159
26902995	The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B.	Sci Rep	2016 Feb 23	Lu S	doi: 10.1038/srep21949.
24888607	Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage.	J Surg Oncol	2014 Sep	Kim TJ	doi: 10.1002/jso.23646
26477488	The mucin MUC4 is a transcriptional and post-transcriptional target of K-ras oncogene in pancreatic cancer. Implication of MAPK/AP-1, NF-κB and RalB signaling pathways.	Biochim Biophys Acta	2015 Dec	Vasseur R	doi: 10.1016/j.bbagrm.2015.10.014
26891420	A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy.	Int J Cancer	2016 Jul 1	Eng C	doi: 10.1002/ijc.30049
21544811	Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer.	Int J Cancer	2012 Apr 15	Sunaga N	doi: 10.1002/ijc.26164
24727325	Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).	Clin Cancer Res	2014 Jun 15	Sha D	doi: 10.1158/1078-0432.CCR-14-0069
22848379	Sensitization of human pancreatic cancer cells harboring mutated K-ras to apoptosis.	PLoS One	2012	Shen L	doi: 10.1371/journal.pone.0040435
24861917	Mutations of KRAS and PIK3CA as independent predictors of distant metastases in colorectal cancer.	Med Oncol	2014 Jul	Zhu K	doi: 10.1007/s12032-014-0016-6
25444464	Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer.	Clin Colorectal Cancer	2014 Dec	Cercek A	doi: 10.1016/j.clcc.2014.09.001
22983505	Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer.	J Gastroenterol	2013 May	Ogura T	doi: 10.1007/s00535-012-0664-2
25609577	KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.	J Clin Pathol	2015 Apr	Malapelle U	doi: 10.1136/jclinpath-2014-202761
22245873	Role of oncogenic pathways and KRAS/BRAF mutations in the behavior of colon adenocarcinoma in renal transplant patients.	Transplantation	2012 Mar 15	Revuelta I	doi: 10.1097/TP.0b013e318242be46.
22459936	KRAS and BRAF mutations in sinonasal cancer.	Oral Oncol	2012 Aug	Lopez F	doi: 10.1016/j.oraloncology.2012.02.018
26977001	The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy.	Anticancer Res	2016 Mar	Svaton M	-
26400062	Ras Signaling Is a Key Determinant for Metastatic Dissemination and Poor Survival of Luminal Breast Cancer Patients.	Cancer Res	2015 Nov 15	Wright KL	doi: 10.1158/0008-5472.CAN-14-2992
24700299	The frequencies and clinical implications of mutations in 33 kinase-related genes in locally advanced rectal cancer: a pilot study.	Ann Surg Oncol	2014 Aug	Abdul-Jalil KI	doi: 10.1245/s10434-014-3658-x
21678640	[Identification of K-RAS mutations in colorectal cancer patients in Israel].	Harefuah	2011 May	Segal G	-
23026567	Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition-mediated cell death in K-ras mutant lung cancer cells.	J Thorac Cardiovasc Surg	2012 Dec	Yu JA	doi: 10.1016/j.jtcvs.2012.08.064
26921316	Aspartate Rescues S-phase Arrest Caused by Suppression of Glutamine Utilization in KRas-driven Cancer Cells.	J Biol Chem	2016 Apr 22	Patel D	doi: 10.1074/jbc.M115.710145
25155261	KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.	Colorectal Dis	2014 Nov	Li W	doi: 10.1111/codi.12749.
20647319	A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.	Cancer Res	2010 Aug 15	Ratner E	doi: 10.1158/0008-5472.CAN-10-0689
22541434	The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.	Cell	2012 Apr 27	Kumar MS	doi: 10.1016/j.cell.2012.02.059.
23161513	Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS.	Mol Cell Proteomics	2013 Feb	Demory Beckler M	doi: 10.1074/mcp.M112.022806
26840022	KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies.	Oncotarget	2016 Feb 16	Pan W	doi: 10.18632/oncotarget.7080.
24889488	KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.	Ann Surg Oncol	2015 Jan	Lee DW	doi: 10.1245/s10434-014-3826-z
24811330	KRAS mutation testing of metastatic colorectal cancer in Australia: where are we at?	Asia Pac J Clin Oncol	2014 Sep	Scott RJ	doi: 10.1111/ajco.12201
20559151	Prognostic implications of epidermal growth factor receptor and KRAS gene mutations and epidermal growth factor receptor gene copy numbers in patients with surgically resectable non-small cell lung cancer in Taiwan.	J Thorac Oncol	2010 Aug	Liu HP	doi: 10.1097/JTO.0b013e3181e2f4d6.
24774510	Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer.	BMC Res Notes	2014 Apr 29	Takahashi N	doi: 10.1186/1756-0500-7-271.
20571907	PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population.	Mol Biol Rep	2011 Feb	Herreros-Villanueva M	doi: 10.1007/s11033-010-0236-6
21949883	Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR.	PLoS One	2011	Santis G	doi: 10.1371/journal.pone.0025191
25713627	Prognostic significance of KRAS gene mutations in colorectal cancer--preliminary study.	J Med Life	2014 Oct-Dec	Dinu D	-
23236152	Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells.	Proc Natl Acad Sci U S A	2012 Dec 26	Weng MT	doi: 10.1073/pnas.1207673110
22982650	Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).	J Thorac Oncol	2012 Oct	Cadranel J	-
27037031	Systematic review: brain metastases from colorectal cancer--Incidence and patient characteristics.	BMC Cancer	2016 Apr 1	Christensen TD	doi: 10.1186/s12885-016-2290-5.
23111797	[The change of pathology in the era of personalized medicine using the example of discordant KRAS mutational status in metastasized colorectal carcinoma].	Dtsch Med Wochenschr	2012 Nov	Hekeler E	doi: 10.1055/s-0032-1327249
21550229	A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer.	Eur J Cancer	2011 Jun	Adelstein BA	doi: 10.1016/j.ejca.2011.03.031
25183481	A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.	Clin Cancer Res	2014 Sep 1	Saridaki Z	doi: 10.1158/1078-0432.CCR-14-0348.
21298467	Clinical validity of detecting K-ras mutations for the diagnosis of exocrine pancreatic cancer: a prospective study in a clinically-relevant spectrum of patients.	Eur J Epidemiol	2011 Mar	Parker LA	doi: 10.1007/s10654-011-9547-8
23657052	KRAS mutational status in Japanese patients with colorectal cancer: results from a nationwide, multicenter, cross-sectional study.	Jpn J Clin Oncol	2013 Jul	Watanabe T	doi: 10.1093/jjco/hyt062
23885463	[Correlation between the presence of Kras mutation and the presence of the proteins epiregulin and amphiregulin in colon cancer tissue].	Harefuah	2013 Jun	Levi Y	-
25248721	Changes of KRAS Exon 2 Codon 12/13 Mutation Status in Recurrent Colorectal Cancer.	Pathol Oncol Res	2015 Apr	Docs O	doi: 10.1007/s12253-014-9834-2
16953233	KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression.	Oncogene	2007 Jan 4	Oliveira C	-
23849768	Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer.	Pathol Biol (Paris)	2013 Dec	Marchoudi N	doi: 10.1016/j.patbio.2013.05.004
23821376	Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.	Target Oncol	2014 Jun	Di Bartolomeo M	doi: 10.1007/s11523-013-0283-8
23264394	Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.	J Clin Endocrinol Metab	2013 Feb	Agrawal N	doi: 10.1210/jc.2012-2703
12372883	p21 and p53 Immunostaining and survival following systemic chemotherapy for urothelial cancer.	Urol Int	2002	Jankevicius F	-
24595526	Mutation status of somatic EGFR and KRAS genes in Chinese patients with prostate cancer (PCa).	Virchows Arch	2014 May	Fu M	doi: 10.1007/s00428-014-1566-x
24806883	Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations.	Oncol Rep	2014 Jul	Ogura T	doi: 10.3892/or.2014.3165
20421765	Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report.	J Thorac Oncol	2010 May	Smit EF	doi: 10.1097/JTO.0b013e3181d86ebf.
26723875	The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.	Cancer Lett	2016 Mar 1	Park KS	doi: 10.1016/j.canlet.2015.12.015
24522420	[KRAS gene mutation in colorectal cancer].	Rev Med Chil	2013 Sep	Roa I	doi: 10.4067/S0034-98872013000900009.
19378369	KRAS mutation in metastatic colorectal cancer and its impact on the use of EGFR inhibitors.	Clin Adv Hematol Oncol	2008 Dec	Lenz HJ	-
23188063	Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer.	Int J Clin Oncol	2013 Dec	Nakanishi R	doi: 10.1007/s10147-012-0501-x
20010090	Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.	Ann Surg	2010 Feb	Yen LC	doi: 10.1097/SLA.0b013e3181bc9d96.
25851630	Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.	Ann Oncol	2015 Aug	Normanno N	doi: 10.1093/annonc/mdv176
18289366	K-ras mutations in sinonasal cancers in relation to wood dust exposure.	BMC Cancer	2008 Feb 20	Bornholdt J	doi: 10.1186/1471-2407-8-53.
22436609	KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study.	BMC Cancer	2012 Mar 22	Cerne JZ	doi: 10.1186/1471-2407-12-105.
22583358	K-ras mutations are correlated to lymph node metastasis and tumor stage, but not to the growth pattern of colon carcinoma.	APMIS	2012 Jun	Mannan A	doi: 10.1111/j.1600-0463.2011.02852.x
25691052	Activation of RAS family members confers resistance to ROS1 targeting drugs.	Oncotarget	2015 Mar 10	Cargnelutti M	-
25778332	Association of rs712 polymorphism in Kras gene 3'-luntranslated region and cancer risk: a meta-analysis.	J BUON	2015 Jan-Feb	Zhao WH	-
23908594	Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems.	Neoplasia	2013 Aug	Nagaria TS	-
23724098	Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.	PLoS One	2013 May 28	Sun JM	doi: 10.1371/journal.pone.0064816
23307237	Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?	Med Oncol	2013 Mar	Kim ST	doi: 10.1007/s12032-012-0328-3
21364589	Activated KrasG12D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin.	Br J Cancer	2011 Mar 15	Rachagani S	doi: 10.1038/bjc.2011.31
15943410	APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.	Am Surg	2005 Apr	Hsieh JS	-
21073737	Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1α and HIF-2α target genes.	Mol Cancer	2010 Nov 13	Chun SY	doi: 10.1186/1476-4598-9-293.
19639197	Mutation detection of KRAS by high-resolution melting analysis in Chinese with gastric cancer.	Oncol Rep	2009 Sep	Liu ZM	-
22213982	[Clinical significance and the handling of KRAS testing on metastatic colorectal cancer].	Nihon Rinsho	2011 Apr	Kawamoto Y	-
19843849	Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer.	Cancer Res	2009 Nov 1	Kikuchi H	doi: 10.1158/0008-5472.CAN-09-2213
24297898	Mutant KRAS is a druggable target for pancreatic cancer.	Proc Natl Acad Sci U S A	2013 Dec 17	Zorde Khvalevsky E	doi: 10.1073/pnas.1314307110
26799289	Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis.	Oncotarget	2016 Feb 16	Fritsche-Guenther R	doi: 10.18632/oncotarget.6959.
22613949	Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.	Cell Res	2012 Aug	Steckel M	doi: 10.1038/cr.2012.82
25997687	RAS status in Korean patients with stage III and IV colorectal cancer.	Clin Transl Oncol	2015 Sep	Lee WS	doi: 10.1007/s12094-015-1301-3
18614859	Shining the spotlight on shed KRAS in pancreatic cancer.	Cancer Biol Ther	2008 Mar	Sempere LF	-
26789109	Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.	Oncotarget	2016 Feb 16	Li W	doi: 10.18632/oncotarget.6671.
22948721	Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.	Oncology	2012	Modest DP	-
26055143	Association of CCND1 overexpression with KRAS and PTEN alterations in specific subtypes of non-small cell lung carcinoma and its influence on patients' outcome.	Tumour Biol	2015 Nov	Dragoj M	doi: 10.1007/s13277-015-3620-y
25253780	Coordinate hyperactivation of Notch1 and Ras/MAPK pathways correlates with poor patient survival: novel therapeutic strategy for aggressive breast cancers.	Mol Cancer Ther	2014 Dec	Mittal S	doi: 10.1158/1535-7163.MCT-14-0280
26725968	Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer.	Mol Oncol	2016 Apr	Tjensvoll K	doi: 10.1016/j.molonc.2015.11.012
27221845	Correlation between RAS Test Results and Prognosis of Metastatic Colorectal Cancer Patients: a Report from Western Iran.	Asian Pac J Cancer Prev	2016	Payandeh M	-
23376846	Heparin-binding epidermal growth factor-like growth factor eliminates constraints on activated Kras to promote rapid onset of pancreatic neoplasia.	Oncogene	2014 Feb 13	Ray KC	doi: 10.1038/onc.2013.3
20100685	KRAS mutation screening in colorectal cancer: From paper to practice.	Clin Colorectal Cancer	2010 Jan	Fakih MM	doi: 10.3816/CCC.2010.n.003.
20645028	Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer.	Med Oncol	2011 Dec	Licar A	doi: 10.1007/s12032-010-9631-z
18075308	Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection.	Cancer Biol Ther	2008 Mar	Shi C	-
22528563	EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma.	Cell Oncol (Dordr)	2012 Jun	Smits AJ	doi: 10.1007/s13402-012-0078-4
20959479	Identification of susceptibility loci in a mouse model of KRASG12D-driven pancreatic cancer.	Cancer Res	2010 Nov 1	Jorgenson TC	doi: 10.1158/0008-5472.CAN-09-3980
23630215	Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.	J Clin Oncol	2013 Jun 10	Shepherd FA	doi: 10.1200/JCO.2012.48.1390
23564819	Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy.	Anticancer Res	2013 Apr	Fiala O	-
25305448	Mutated K-ras activates CDK8 to stimulate the epithelial-to-mesenchymal transition in pancreatic cancer in part via the Wnt/β-catenin signaling pathway.	Cancer Lett	2015 Jan 28	Xu W	doi: 10.1016/j.canlet.2014.10.008
25427581	Efficacy of triplet combination chemotherapy with oxaliplatin, irinotecan and capecitabine (OCX) in metastatic colorectal cancer in relation to RAS/RAF mutation status: results of a retrospective analysis.	Oncol Res Treat	2014	Brunner S	doi: 10.1159/000368313
15923428	Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies.	Ann Oncol	2005 May	Russo A	-
19546608	KRAS mutation testing in colorectal cancer.	Adv Anat Pathol	2009 Jul	Plesec TP	doi: 10.1097/PAP.0b013e3181a9d4ed.
25864038	KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer.	Mol Oncol	2015 Aug	Deng Y	doi: 10.1016/j.molonc.2015.03.006
23806795	Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist?	Lung Cancer	2013 Sep	Bauml J	doi: 10.1016/j.lungcan.2013.05.011
26049686	Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.	Eur J Cancer	2015 Sep	Peeters M	doi: 10.1016/j.ejca.2015.05.017
19137007	Role of miR-143 targeting KRAS in colorectal tumorigenesis.	Oncogene	2009 Mar 12	Chen X	doi: 10.1038/onc.2008.474
21483104	Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing.	Anal Cell Pathol (Amst)	2011	Richman SD	doi: 10.3233/ACP-2011-0005.
25245423	MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells.	Oncotarget	2014 Oct 15	Kharbanda A	-
21795973	Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status.	Anticancer Drugs	2011 Oct	Modest DP	doi: 10.1097/CAD.0b013e3283493160.
20233436	Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study.	BMC Cancer	2010 Mar 16	Naguib A	doi: 10.1186/1471-2407-10-99.
17198183	K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking.	Pancreas	2007 Jan	Jiao L	-
22586484	KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer.	PLoS One	2012	Mao C	doi: 10.1371/journal.pone.0036653
19824059	Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.	J Pathol	2009 Dec	Abubaker J	doi: 10.1002/path.2625.
26299805	Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance.	Oncotarget	2015 Aug 28	Morkel M	-
15534934	Co-mutation of p53, K-ras genes and accumulation of p53 protein and its correlation to clinicopathological features in rectal cancer.	World J Gastroenterol	2004 Dec 15	Pan ZZ	-
24715238	Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen.	Int J Oncol	2014 Jun	Bruera G	doi: 10.3892/ijo.2014.2369
19603024	Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.	Br J Cancer	2009 Aug 4	Souglakos J	doi: 10.1038/sj.bjc.6605164
22082529	Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant cancer cells.	Cancer Lett	2012 Mar	Yoon YK	doi: 10.1016/j.canlet.2011.10.023
24349411	Comparative analysis of radiosensitizers for K-RAS mutant rectal cancers.	PLoS One	2013 Dec 12	Kleiman LB	doi: 10.1371/journal.pone.0082982
24675495	Clinico-pathological study of K-ras mutations in colorectal tumors in Saudi Arabia.	Tumori	2014 Jan-Feb	Zahrani A	doi: 10.1700/1430.15819.
23975373	A let-7 KRAS rs712 polymorphism increases colorectal cancer risk.	Tumour Biol	2014 Jan	Pan XM	doi: 10.1007/s13277-013-1114-3
19678923	Presence of activating KRAS mutations correlates significantly with expression of tumour suppressor genes DCN and TPM1 in colorectal cancer.	BMC Cancer	2009 Aug 13	Mlakar V	doi: 10.1186/1471-2407-9-282.
27100819	Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review.	JAMA Oncol	2016 Jun 1	Wood K	doi: 10.1001/jamaoncol.2016.0405.
22988093	Selective requirement for Mediator MED23 in Ras-active lung cancer.	Proc Natl Acad Sci U S A	2012 Oct 9	Yang X	doi: 10.1073/pnas.1204311109
21127395	Increased expression of annexin A1 is correlated with K-ras mutation in colorectal cancer.	Tohoku J Exp Med	2010 Dec	Su N	-
23284732	Microsatellite instability, KRAS mutations and cellular distribution of TRAIL-receptors in early stage colorectal cancer.	PLoS One	2012	Kriegl L	doi: 10.1371/journal.pone.0051654
23027075	KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab.	Br J Surg	2012 Nov	Stremitzer S	doi: 10.1002/bjs.8909.
21036740	Inhibition of Myc effectively targets KRAS mutation-positive lung cancer expressing high levels of Myc.	Anticancer Res	2010 Oct	Fukazawa T	-
25950441	Detection of K-ras Mutations in Predicting Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitor in Patients with Metastatic Colorectal Cancer.	PLoS One	2015 May 7	Li Z	doi: 10.1371/journal.pone.0101019
23090619	Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis.	Cancer Chemother Pharmacol	2013 Jan	Chen J	doi: 10.1007/s00280-012-2005-9
18049799	The association between selected risk factors for pancreatic cancer and the expression of p53 and K-ras codon 12 mutations.	Int J Gastrointest Cancer	2006	Fryzek JP	-
17534846	Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas.	J Pathol	2007 Jul	Sakamoto H	-
22972628	KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis.	Cancer	2013 Feb 15	Mao C	doi: 10.1002/cncr.27804
24629489	KRAS mutational analysis in ductal adenocarcinoma of the pancreas and its clinical significance.	Pathol Res Pract	2014 May	Miglio U	doi: 10.1016/j.prp.2014.01.011
27184911	Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics.	Pathol Res Pract	2016 Jul	Krajnovic M	doi: 10.1016/j.prp.2016.02.018
15221969	Peptide nucleic acid clamp PCR: a novel K-ras mutation detection assay for colorectal cancer micrometastases in lymph nodes.	Int J Cancer	2004 Sep 1	Taback B	-
22753589	Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers.	Clin Cancer Res	2012 Sep 1	Imamura Y	doi: 10.1158/1078-0432.CCR-11-3210
23645765	KRAS mutations in patients with colorectal cancer as detected by high-resolution melting analysis and direct sequencing.	Anticancer Res	2013 May	Akiyoshi K	-
23355875	Detection of low-abundance KRAS mutations in colorectal cancer using microfluidic capillary electrophoresis-based restriction fragment length polymorphism method with optimized assay conditions.	PLoS One	2013	Zhang H	doi: 10.1371/journal.pone.0054510
26121270	High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort.	PLoS One	2015 Jun 29	Sorbye H	doi: 10.1371/journal.pone.0131046
26262587	Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells.	Pancreas	2016 Feb	Lee S	doi: 10.1097/MPA.0000000000000379.
21510309	Long-term follow-up of chronic pancreatitis patients with K-ras mutation in the pancreatic juice.	Hepatogastroenterology	2011 Jan-Feb	Kamisawa T	-
19884549	KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.	J Clin Oncol	2009 Dec 10	Richman SD	doi: 10.1200/JCO.2009.22.4295
19921572	[Effect of KRAS mutation on efficacy of Cetuximab combined with chemotherapy in advanced colorectal cancer patients].	Zhonghua Wei Chang Wai Ke Za Zhi	2009 Nov	Pu XX	-
22865324	Study of KRAS new predictive marker in a clinical laboratory.	Clin Transl Oncol	2012 Dec	Bando I	doi: 10.1007/s12094-012-0886-z
22876814	Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer.	BMC Cancer	2012 Aug 9	Kim MJ	doi: 10.1186/1471-2407-12-347.
23608713	Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis.	Lung Cancer	2013 Jul	Meng D	doi: 10.1016/j.lungcan.2013.03.019
23324583	Duplex reverse-hybridization assay for the simultaneous detection of KRAS/BRAF mutations in FFPE-extracted genomic DNA from colorectal cancer specimens.	Dis Markers	2013	Buxhofer-Ausch V	doi: 10.3233/DMA-120960.
21720997	Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.	Cancer	2012 Feb 1	Kim HR	doi: 10.1002/cncr.26311
27179269	Concordance of KRAS mutation status between luminal and peripheral regions of primary colorectal cancer. A laser-capture microdissection-based study.	Pol J Pathol	2016 Mar	Lewandowska M	-
24040001	Differential expression of IL-17, 22 and 23 in the progression of colorectal cancer in patients with K-ras mutation: Ras signal inhibition and crosstalk with GM-CSF and IFN-γ.	PLoS One	2013 Sep 6	Petanidis S	doi: 10.1371/journal.pone.0073616
21441955	Mutant K-Ras increases GSK-3β gene expression via an ETS-p300 transcriptional complex in pancreatic cancer.	Oncogene	2011 Aug 25	Zhang JS	doi: 10.1038/onc.2011.90
26616508	Targeting BRAF aberrations in advanced colorectal carcinoma: from bench to bedside.	Future Oncol	2016 Jan	Abdel-Rahman O	doi: 10.2217/fon.15.226
23224736	Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas.	Clin Cancer Res	2013 Feb 15	McCleland ML	doi: 10.1158/1078-0432.CCR-12-2638
20563851	KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer.	Mol Biol Rep	2011 Feb	Herreros-Villanueva M	doi: 10.1007/s11033-010-0232-x
18386236	Relationship between overexpression of ras p21 oncoprotein and K-ras codon 12 and 13 mutations in Turkish colorectal cancer patients.	Turk J Gastroenterol	2008 Mar	Akkiprik M	-
25628445	Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.	Ann Oncol	2015 Apr	Morelli MP	doi: 10.1093/annonc/mdv005
17596643	Clinical features reflect exon sites of EGFR mutations in patients with resected non-small-cell lung cancer.	J Korean Med Sci	2007 Jun	Na II	-
12093899	Mutations in APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancer.	Proc Natl Acad Sci U S A	2002 Jul 9	Smith G	-
25401377	Effective suppression of the Kirsten rat sarcoma viral oncogene in pancreatic tumor cells via targeted small interfering RNA delivery using nanoparticles.	Pancreas	2015 Mar	Zeng L	doi: 10.1097/MPA.0000000000000241.
21497370	EGFR and KRAS mutations in metastatic lung adenocarcinomas.	Hum Pathol	2011 Oct	Munfus-McCray D	doi: 10.1016/j.humpath.2010.12.011
25742883	High MACC1 expression in combination with mutated KRAS G13 indicates poor survival of colorectal cancer patients.	Mol Cancer	2015 Feb 14	Ilm K	doi: 10.1186/s12943-015-0316-2.
22791568	Involvement of K-RAS mutations and amino acid substitutions in the survival of metastatic colorectal cancer patients.	Tumour Biol	2012 Dec	Perez-Ruiz E	doi: 10.1007/s13277-012-0442-z
22043994	Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?	Anticancer Agents Med Chem	2012 Feb	Yokota T	-
15037631	p38 MAPK activation selectively induces cell death in K-ras-mutated human colon cancer cells through regulation of vitamin D receptor.	J Biol Chem	2004 May 21	Qi X	-
24893629	A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer.	Clin Cancer Res	2014 Aug 1	Vasan N	doi: 10.1158/1078-0432.CCR-13-1762
26649302	Black Rice Anthocyanins Suppress Metastasis of Breast Cancer Cells by Targeting RAS/RAF/MAPK Pathway.	Biomed Res Int	2015	Chen XY	doi: 10.1155/2015/414250
23392229	Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma.	J Thorac Oncol	2013 Apr	Yip PY	doi: 10.1097/JTO.0b013e318283558e.
26970738	Copy number of the Adenomatous Polyposis Coli gene is not always neutral in sporadic colorectal cancers with loss of heterozygosity for the gene.	BMC Cancer	2016 Mar 12	Zauber P	doi: 10.1186/s12885-016-2243-z.
24139827	Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.	Clin Lung Cancer	2014 Jan	Metro G	doi: 10.1016/j.cllc.2013.08.002
22635024	Genome-wide single nucleotide polymorphism arrays as a diagnostic tool in patients with synchronous endometrial and ovarian cancer.	Int J Gynecol Cancer	2012 Jun	Ikeda Y	doi: 10.1097/IGC.0b013e31824c6ea6.
18199160	Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.	Pathol Int	2008 Feb	Lee S	doi: 10.1111/j.1440-1827.2007.02197.x.
26684803	KRAS mutations in pancreatic circulating tumor cells: a pilot study.	Tumour Biol	2016 Jun	Kulemann B	doi: 10.1007/s13277-015-4589-2
26432508	Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy.	Clin Lung Cancer	2016 Jan	Goldman JW	doi: 10.1016/j.cllc.2015.08.003
23302304	[Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system].	Zhonghua Bing Li Xue Za Zhi	2012 Oct	Gao J	doi: 10.3760/cma.j.issn.0529-5807.2012.10.002.
18202412	KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.	J Clin Oncol	2008 Jan 20	Lièvre A	doi: 10.1200/JCO.2007.12.5906.
23098991	MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF.	Cancer Genet	2012 Nov	Mosakhani N	doi: 10.1016/j.cancergen.2012.08.003
24205021	Can K-ras gene mutation be utilized as prognostic biomarker for colorectal cancer patients receiving chemotherapy? A meta-analysis and systematic review.	PLoS One	2013 Oct 21	Rui YY	doi: 10.1371/journal.pone.0077901
24687927	KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).	Clin Cancer Res	2014 Jun 1	Yoon HH	doi: 10.1158/1078-0432.CCR-13-3140
16112461	Mutant KRAS, chromosomal instability and prognosis in colorectal cancer.	Biochim Biophys Acta	2005 Nov 25	Castagnola P	-
20652953	The prognostic value of c-Kit, K-ras codon 12, and p53 codon 72 mutations in Egyptian patients with stage II colorectal cancer.	Cancer	2010 Nov 1	El-Serafi MM	doi: 10.1002/cncr.25417.
22938585	High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues.	Arch Pathol Lab Med	2012 Sep	Ney JT	doi: 10.5858/arpa.2011-0176-OA.
24651628	The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer.	Int J Gynecol Cancer	2014 May	Meyer LA	doi: 10.1097/IGC.0000000000000118.
23965232	TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.	Exp Mol Pathol	2013 Oct	Rechsteiner M	doi: 10.1016/j.yexmp.2013.08.004
14513361	Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers.	Hum Genet	2003 Dec	Kim IJ	-
26820797	Pre-clinical use of isogenic cell lines and tumours invitro and invivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent.	Eur J Cancer	2016 Mar	Haagensen EJ	doi: 10.1016/j.ejca.2015.12.012
23456389	Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma.	Ann Surg Oncol	2013 Jul	Duldulao MP	doi: 10.1245/s10434-013-2910-0
21508389	Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer.	Anticancer Res	2011 Apr	De Bruijn MT	-
20681447	[K-RAS gene mutations in patients with non-small cell lung cancer].	Zhongguo Fei Ai Za Zhi	2010 Jun	Zhang Y	doi: 10.3779/j.issn.1009-3419.2010.06.007.
26220150	Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer.	Cancer Treat Rev	2015 Sep	Hecht JR	doi: 10.1016/j.ctrv.2015.05.008
26281864	Correlation between DPYD gene variation and KRAS wild type status in colorectal cancer.	J Clin Pathol	2016 Mar	Kleist B	doi: 10.1136/jclinpath-2015-202903
23526092	Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians.	Tumour Biol	2013 Jun	Malhotra P	doi: 10.1007/s13277-013-0734-y
26525741	High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment.	BMC Cancer	2015 Nov 2	Deng Y	doi: 10.1186/s12885-015-1840-6.
25823645	Eprobe-mediated screening system for somatic mutations in the KRAS locus.	Oncol Rep	2015 Jun	Atsumi J	doi: 10.3892/or.2015.3883
25491172	RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer.	Cancer	2015 Apr 15	Yaeger R	doi: 10.1002/cncr.29196
26927447	KRAS, BRAF, and PIK3CA mutations, and patient prognosis in 126 pancreatic cancers: pyrosequencing technology and literature review.	Med Oncol	2016 Apr	Zhou L	doi: 10.1007/s12032-016-0745-9
26771140	CXCR2 signaling regulates KRAS(G12D)-induced autocrine growth of pancreatic cancer.	Oncotarget	2016 Feb 9	Purohit A	doi: 10.18632/oncotarget.6906.
17184525	High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer.	BMC Cancer	2006 Dec 21	Krypuy M	-
21155011	Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer.	World J Gastroenterol	2010 Dec 14	Li FH	-
23199549	Kras mutations and p53 overexpression in pseudomyxoma peritonei: association with phenotype and prognosis.	J Surg Res	2013 Mar	Shetty S	doi: 10.1016/j.jss.2012.10.053
21699410	Comparison of KRAS mutation tests in colorectal cancer patients.	Genet Test Mol Biomarkers	2011 Nov	Hancer VS	doi: 10.1089/gtmb.2011.0027
24681874	KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.	Pancreas	2014 May	Sinn BV	doi: 10.1097/MPA.0000000000000077.
20049979	KRAS mutation analysis on cytological specimens of metastatic colo-rectal cancer.	Diagn Cytopathol	2010 Dec	Troncone G	doi: 10.1002/dc.21302.
22662244	The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer.	PLoS One	2012	Pilarski R	doi: 10.1371/journal.pone.0037891
23514584	Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma.	Acta Oncol	2013 Jun	Spindler KL	doi: 10.3109/0284186X.2013.776175
17671710	Nras and Kras mutation in Japanese lung cancer patients: Genotyping analysis using LightCycler.	Oncol Rep	2007 Sep	Sasaki H	-
22735045	[Observational study on conditions for access to the analysis of KRAS mutation in patients with metastatic colorectal cancer receiving panitumumab treatment].	Bull Cancer	2012 Jul-Aug	Bibeau F	doi: 10.1684/bdc.2012.1612.
26747707	Transcriptional Regulation of miR-31 by Oncogenic KRAS Mediates Metastatic Phenotypes by Repressing RASA1.	Mol Cancer Res	2016 Mar	Kent OA	doi: 10.1158/1541-7786.MCR-15-0456
23473612	The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011.	Eur J Cancer	2013 Jun	Lievre A	doi: 10.1016/j.ejca.2013.02.016
21862683	Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy.	Mol Cancer Ther	2011 Oct	Kim ST	doi: 10.1158/1535-7163.MCT-11-0269
26418750	Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy.	Oncotarget	2015 Oct 13	Alves S	doi: 10.18632/oncotarget.5021.
25302858	Comparison of PNA clamping and direct sequencing for detecting KRAS mutations in matched tumour tissue, cell block, pleural effusion and serum from patients with malignant pleural effusion.	Respirology	2015 Jan	Kang JY	doi: 10.1111/resp.12413
24973952	EGFR and KRAS mutations in Turkish non-small cell lung cancer patients: a pilot study.	Med Oncol	2014 Aug	Bircan S	doi: 10.1007/s12032-014-0087-4
22922794	The prognostic value of KRAS mutations in patients with colorectal cancer.	Oncol Rep	2012 Nov	Inoue Y	doi: 10.3892/or.2012.1974
21447798	Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.	Sci Signal	2011 Mar 29	Little AS	doi: 10.1126/scisignal.2001752.
21436632	Clinically important molecular features of Peruvian colorectal tumours: high prevalence of DNA mismatch repair deficiency and low incidence of KRAS mutations.	Pathology	2011 Apr	Egoavil CM	doi: 10.1097/PAT.0b013e3283437613.
21174225	Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.	Invest New Drugs	2012 Apr	Shitara K	doi: 10.1007/s10637-010-9615-z
21555681	KRAS-mutation positive, metastatic tonsil carcinoma with cancer stem-like cell features and long-term response to gefitinib: a case report and review of the literature.	J Clin Oncol	2011 Jul 20	Gottschling S	doi: 10.1200/JCO.2011.34.5892
24389431	Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression.	J Thorac Oncol	2013 Dec	Guin S	doi: 10.1097/JTO.0000000000000007.
20482381	A novel mutant-enriched liquidchip technology for the qualitative detection of somatic mutations in KRAS gene from both serum and tissue samples.	Clin Chem Lab Med	2010 Aug	Wu S	doi: 10.1515/CCLM.2010.227.
23752186	EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis.	Oncogene	2014 May 8	Tanaka M	doi: 10.1038/onc.2013.204
25689095	Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).	Respirology	2015 Apr	Kumarakulasinghe NB	doi: 10.1111/resp.12490
21074889	The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients.	Lung Cancer	2011 Jun	Camps C	doi: 10.1016/j.lungcan.2010.09.005
20871266	A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound- and endobronchial ultrasound-guided fine needle cytological aspirates.	J Thorac Oncol	2010 Oct	Schuurbiers OC	doi: 10.1097/JTO.0b013e3181f0bd93.
25956913	Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis.	BMC Cancer	2015 May 9	Mortazavi F	doi: 10.1186/s12885-015-1360-4.
18577988	Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients.	Br J Cancer	2008 Jul 8	Cappuzzo F	doi: 10.1038/sj.bjc.6604439
19002263	Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample.	PLoS One	2008	Nosho K	doi: 10.1371/journal.pone.0003698
26716649	Simultaneous gene silencing of KRAS and anti-apoptotic genes as a multitarget therapy.	Oncotarget	2016 Jan 26	Werner K	doi: 10.18632/oncotarget.6766.
26775593	Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆.	Lung Cancer	2016 Feb	Hames ML	doi: 10.1016/j.lungcan.2015.11.004
26648033	Regulatory single nucleotide polymorphisms at the beginning of intron 2 of the human KRAS gene.	J Biosci	2015 Dec	Antontseva EV	-
25164765	Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.	Genome Biol	2014 Aug 28	Brannon AR	doi: 10.1186/s13059-014-0454-7.
21031422	Genetic alterations of K-ras may reflect prognosis in stage III colon cancer patients below 60 years of age.	J Surg Oncol	2011 Jan 1	Onozato W	doi: 10.1002/jso.21710.
22510757	Phenotype and polyp landscape in serrated polyposis syndrome: a series of 100 patients from genetics clinics.	Am J Surg Pathol	2012 Jun	Rosty C	doi: 10.1097/PAS.0b013e31824e133f.
22139083	A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.	Oncogene	2012 Oct 18	Ratner ES	doi: 10.1038/onc.2011.539
25666295	FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.	Clin Colorectal Cancer	2015 Jun	Kaczirek K	doi: 10.1016/j.clcc.2014.12.003
23435671	KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer.	J Gastroenterol	2013 Apr	Boeck S	doi: 10.1007/s00535-013-0767-4
19745602	LIN28B confers radio-resistance through the posttranscriptional control of KRAS.	Exp Mol Med	2009 Dec 31	Jeong SH	doi: 10.3858/emm.2009.41.12.097.
28179313	Comparative Study of Mutations in Single Nucleotide Polymorphism Loci of KRAS and BRAF Genes in Patients Who Underwent Screening Colonoscopy, With and Without Premalignant Intestinal Polyps.	Anticancer Res	2017 Feb	Galanopoulos M	-
24956168	Panel based MALDI-TOF tumour profiling is a sensitive method for detecting mutations in clinical non small cell lung cancer tumour.	PLoS One	2014 Jun 23	Sherwood JL	doi: 10.1371/journal.pone.0100566
25577224	Should KRAS mutation still be used as a routine predictor of response to EGFR-TKIs in advanced non-small-cell lung cancer? A revaluation based on meta-analysis.	J Cancer Res Clin Oncol	2015 Aug	Ying M	doi: 10.1007/s00432-015-1910-9
22000810	The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.	Clin Colorectal Cancer	2011 Dec	Mitchell EP	doi: 10.1016/j.clcc.2011.06.004
25023699	Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs.	Oncogene	2015 May 14	Saqcena M	doi: 10.1038/onc.2014.207
22526587	KRAS mutation and NF-κB activation indicates tolerance of chemotherapy and poor prognosis in colorectal cancer.	Dig Dis Sci	2012 Sep	Lin G	doi: 10.1007/s10620-012-2172-x
25561800	Comparative study of mutations in SNP loci of K-RAS, hMLH1 and hMSH2 genes in neoplastic intestinal polyps and colorectal cancer.	World J Gastroenterol	2014 Dec 28	Yan ZH	doi: 10.3748/wjg.v20.i48.18338.
23341890	Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.	PLoS One	2013	Li Y	doi: 10.1371/journal.pone.0052093
19096301	Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).	J Thorac Oncol	2009 Jan	Lim EH	doi: 10.1097/JTO.0b013e3181913e28.
24696490	Permissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activity.	J Virol	2014 Jun	Cuddington BP	doi: 10.1128/JVI.00849-14
22638623	Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.	Int J Clin Oncol	2013 Aug	Soeda H	doi: 10.1007/s10147-012-0422-8
22929917	Association of folate intake, dietary habits, smoking and COX-2 promotor -765G>C polymorphism with K-ras mutation in patients with colorectal cancer.	J Egypt Natl Canc Inst	2012 Sep	Kamal MM	doi: 10.1016/j.jnci.2012.05.002
18265644	The differentially mutational spectra of the APC, K-ras, and p53 genes in sporadic colorectal cancers from Taiwanese patients.	Hepatogastroenterology	2007 Dec	Wang JY	-
19661383	Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells.	Science	2009 Sep 18	Yun J	doi: 10.1126/science.1174229
12972432	Oncogenic Ki-ras inhibits the expression of interferon-responsive genes through inhibition of STAT1 and STAT2 expression.	J Biol Chem	2003 Nov 21	Klampfer L	-
26498594	Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.	BMC Cancer	2015 Oct 24	Earl J	doi: 10.1186/s12885-015-1779-7.
24024839	Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.	N Engl J Med	2013 Sep 12	Douillard JY	doi: 10.1056/NEJMoa1305275.
21910869	Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy.	Radiat Oncol	2011 Sep 12	Davies JM	doi: 10.1186/1748-717X-6-114.
21390154	Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients.	World J Gastroenterol	2011 Feb 14	Shen H	doi: 10.3748/wjg.v17.i6.809.
23524403	KRAS mutations as prognostic and predictive markers in non-small cell lung cancer.	J Thorac Oncol	2013 May	Martin P	doi: 10.1097/JTO.0b013e318283d958.
23625655	Are high initial CEA and CA 19-9 levels associated with the presence of K-ras mutation in patients with metastatic colorectal cancer?	Tumour Biol	2013 Aug	Selcukbiricik F	doi: 10.1007/s13277-013-0763-6
26316738	A variant in 3'-untranslated region of KRAS compromises its interaction with hsa-let-7g and contributes to the development of lung cancer in patients with COPD.	Int J Chron Obstruct Pulmon Dis	2015 Aug 17	Hu H	doi: 10.2147/COPD.S83596
23157824	[KRAS and BRAF gene mutations in correlation with clinicopathologic features of colorectal carcinoma in Chinese].	Zhonghua Bing Li Xue Za Zhi	2012 Sep	Zhu XL	doi: 10.3760/cma.j.issn.0529-5807.2012.09.003.
19574674	Mutation pattern of K-ras gene in colorectal cancer patients of Kashmir: a report.	Indian J Cancer	2009 Jul-Sep	Sameer AS	doi: 10.4103/0019-509X.52956.
25499080	Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.	Cancer Lett	2015 Feb 28	Yang L	doi: 10.1016/j.canlet.2014.12.003
25663768	MiR-21/RASA1 axis affects malignancy of colon cancer cells via RAS pathways.	World J Gastroenterol	2015 Feb 7	Gong B	doi: 10.3748/wjg.v21.i5.1488.
21169348	Tumor KRAS status predicts responsiveness to panitumumab in Japanese patients with metastatic colorectal cancer.	Jpn J Clin Oncol	2011 Feb	Doi T	doi: 10.1093/jjco/hyq229
22964644	Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.	Oncogene	2013 Aug 22	Sunaga N	doi: 10.1038/onc.2012.402
21239505	KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.	Clin Cancer Res	2011 Mar 1	Tie J	doi: 10.1158/1078-0432.CCR-10-1720
19637313	TRAIL receptor upregulation and the implication of KRAS/BRAF mutations in human colon cancer tumors.	Int J Cancer	2009 Nov 1	Oikonomou E	doi: 10.1002/ijc.24613.
23755178	Prognostic significance of C-reactive protein polymorphism and KRAS/BRAF in synchronous liver metastasis from colorectal cancer.	PLoS One	2013 Jun 3	Huang CJ	doi: 10.1371/journal.pone.0065117
17549340	Detection of activated K-ras in non-small cell lung cancer by membrane array: a comparison with direct sequencing.	Oncol Rep	2007 Jul	Chong IW	-
21985784	Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.	J Clin Invest	2011 Nov	Ebi H	doi: 10.1172/JCI57909
24011934	Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.	Eur J Cancer	2013 Dec	Sheppard KE	doi: 10.1016/j.ejca.2013.08.007
23238036	The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.	Lung Cancer	2013 Mar	Nygaard AD	doi: 10.1016/j.lungcan.2012.11.016
22672749	KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.	Int J Radiat Oncol Biol Phys	2013 Jan 1	Kim SY	doi: 10.1016/j.ijrobp.2012.03.048
26610798	KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study.	Mol Diagn Ther	2016 Feb	Dadduzio V	doi: 10.1007/s40291-015-0178-8.
22386733	Absence of evidence for epidermal growth factor receptor and human homolog of the Kirsten rat sarcoma-2 virus oncogene mutations in breast cancer.	Cancer Epidemiol	2012 Aug	Lv N	doi: 10.1016/j.canep.2012.01.004
23838952	Prognostic significance of K-ras codon 12 mutation in patients with resected gallbladder cancer.	Dig Surg	2013	Kazmi HR	doi: 10.1159/000353133
24890702	Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis.	Cancer Med	2014 Oct	Langevin SM	doi: 10.1002/cam4.279
24219000	K-Ras, intestinal homeostasis and colon cancer.	Curr Clin Pharmacol	2015	Goel S	-
12826308	K-ras mutations in lung carcinomas from nonsmoking women exposed to unvented coal smoke in China.	Lung Cancer	2003 Jul	Keohavong P	-
25197873	KRAS and PIK3CA mutation frequencies in patient-derived xenograft models of pancreatic and colorectal cancer are reflective of patient tumors and stable across passages.	Am Surg	2014 Sep	Tignanelli CJ	-
21435948	A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis.	Lancet Oncol	2011 Apr	Paranjape T	doi: 10.1016/S1470-2045(11)70044-4
22044911	K-ras mutations in the plasma correspond to computed tomographic findings in patients with pancreatic cancer.	Pancreas	2012 Mar	Dabritz J	doi: 10.1097/MPA.0b013e3182289118.
26740498	Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC.	J Int Med Res	2016 Feb	Zhou H	doi: 10.1177/0300060515607383
24594201	Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients.	Genet Res (Camb)	2014	Carneiro JG	doi: 10.1017/S0016672314000032
24582914	RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial.	Eur J Cancer	2014 May	Sclafani F	doi: 10.1016/j.ejca.2014.02.002
21252116	IMP-1 displays cross-talk with K-Ras and modulates colon cancer cell survival through the novel proapoptotic protein CYFIP2.	Cancer Res	2011 Mar 15	Mongroo PS	doi: 10.1158/0008-5472.CAN-10-3295
25699356	Significance of KRAS mutation in patients receiving mFOLFOX6 with or without bevacizumab for metastatic colorectal cancer.	Hepatogastroenterology	2014 Nov-Dec	Koike J	-
24947927	Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.	Clin Cancer Res	2014 Aug 15	Zimmer L	doi: 10.1158/1078-0432.CCR-14-0341
24122611	EGFR, KRAS, BRAF, and PIK3CA characterization in squamous cell anal cancer.	Histol Histopathol	2014 Apr	Martin V	doi: 10.14670/HH-29.10.513
26636714	Combined Delivery of Let-7b MicroRNA and Paclitaxel via Biodegradable Nanoassemblies for the Treatment of KRAS Mutant Cancer.	Mol Pharm	2016 Feb 1	Dai X	doi: 10.1021/acs.molpharmaceut.5b00756
23155138	KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings.	Cancer Epidemiol Biomarkers Prev	2013 Jan	Webster J	doi: 10.1158/1055-9965.EPI-12-0545
20575464	Comparison of two different screening methods for the KRAS mutation in colorectal cancer.	Clin Lab	2010	Er TK	-
24440976	Somatic gene mutations in African Americans may predict worse outcomes in colorectal cancer.	Cancer Biomark	2013	Kang M	doi: 10.3233/CBM-130366.
27466537	Lack of Relationship Between Clinical Features and KRAS Mutations in Patients with Metastatic Colorectal Cancer.	Anticancer Res	2016 Aug	Ploquin A	-
22489692	Mutation pattern of KRAS and BRAF oncogenes in colorectal cancer patients.	Neoplasma	2012	Rako I	doi: 10.4149/neo_2012_049.
15514939	A novel high-specificity approach for colorectal neoplasia: Detection of K-ras2 oncogene mutation in normal mucosa.	Int J Cancer	2005 Mar 1	Yamada S	-
17998284	KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.	Ann Oncol	2008 Mar	De Roock W	-
19936839	KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy.	Ann Surg Oncol	2010 Apr	Siddiqui AD	doi: 10.1245/s10434-009-0811-z
19813061	KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer.	Ann Surg Oncol	2010 Feb	Nash GM	doi: 10.1245/s10434-009-0713-0
25929517	Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages.	BMC Cancer	2015 May 1	Li W	doi: 10.1186/s12885-015-1345-3.
21742770	STK33 kinase activity is nonessential in KRAS-dependent cancer cells.	Cancer Res	2011 Sep 1	Babij C	doi: 10.1158/0008-5472.CAN-11-0778
17629419	K-ras mutation detection in colorectal cancer using the Pyrosequencing technique.	Pathol Res Pract	2007	Poehlmann A	-
22535956	Novel AKT1-GLI3-VMP1 pathway mediates KRAS oncogene-induced autophagy in cancer cells.	J Biol Chem	2012 Jul 20	Lo Ré AE	doi: 10.1074/jbc.M112.370809
26325669	Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.	Oncotarget	2015 Sep 22	Formisano L	doi: 10.18632/oncotarget.4636.
19281127	[K-ras mutation predictive significance in platinum based chemotherapeutic protocols in patients with advanced non-small cell lung cancer].	Vojnosanit Pregl	2009 Feb	Cvetkovic G	-
21855038	An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.	Clin Colorectal Cancer	2011 Sep	Cohn AL	doi: 10.1016/j.clcc.2011.03.022
26384309	Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients.	Oncotarget	2015 Oct 13	Vincenzi B	doi: 10.18632/oncotarget.5231.
26429158	KRAS gene mutations - prognostic factor in colorectal cancer?	Rom J Morphol Embryol	2015	Dobre M	-
26028668	High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.	Oncotarget	2015 May 10	Thomas A	-
17704924	Genetic alterations of APC, K-ras, p53, MSI, and MAGE in Korean colorectal cancer patients.	Int J Colorectal Dis	2008 Jan	Jeon CH	-
25050586	KRAS and BRAF mutations and MSI status in precursor lesions of colorectal cancer detected by colonoscopy.	Oncol Rep	2014 Oct	Yamane LS	doi: 10.3892/or.2014.3338
26925650	Mutation Analysis of KRAS and BRAF Genes in Metastatic Colorectal Cancer: a First Large Scale Study from Iran.	Asian Pac J Cancer Prev	2016	Koochak A	-
26028111	KRAS Mutation as a Biomarker for Survival in Patients with Non-Small Cell Lung Cancer, A Meta-Analysis of 12 Randomized Trials.	Asian Pac J Cancer Prev	2015	Ying M	-
22016105	Molecular morphometric analysis shows relative intra-tumoural homogeneity for KRAS mutations in colorectal cancer.	Virchows Arch	2011 Nov	Farber L	doi: 10.1007/s00428-011-1158-y
21947301	EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy.	J Clin Pathol	2011 Oct	Thunnissen E	doi: 10.1136/jclinpath-2011-200163.
22113502	Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo.	Oncotarget	2011 Nov	Qiu W	-
24172884	Androgen receptor decreases CMYC and KRAS expression by upregulating let-7a expression in ER-, PR-, AR+ breast cancer.	Int J Oncol	2014 Jan	Lyu S	doi: 10.3892/ijo.2013.2151
27793187	A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS.	Chin J Cancer	2016 Oct 28	Pang X	-
26802155	Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.	Ann Oncol	2016 Apr	Carter CA	doi: 10.1093/annonc/mdw008
19671843	Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.	Clin Cancer Res	2009 Aug 15	Jackman DM	doi: 10.1158/1078-0432.CCR-09-0888
26544625	Oncogenic Ras suppresses ING4-TDG-Fas axis to promote apoptosis resistance.	Oncotarget	2015 Dec 8	Sun J	doi: 10.18632/oncotarget.6015.
21847063	A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.	J Thorac Oncol	2011 Aug	Riely GJ	doi: 10.1097/JTO.0b013e318223c099.
16969076	Recurrent KRAS codon 146 mutations in human colorectal cancer.	Cancer Biol Ther	2006 Aug	Edkins S	-
27356691	Oncogenic Activation of Fibroblast Growth Factor Receptor-3 and RAS Genes as Non-Overlapping Mutual Exclusive Events in Urinary Bladder Cancer.	Asian Pac J Cancer Prev	2016	Pandith AA	-
19847166	Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.	Nature	2009 Nov 5	Barbie DA	doi: 10.1038/nature08460
26077004	Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.	Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub	2015 Sep	Uvirova M	doi: 10.5507/bp.2015.029
27509933	Evaluation of KRAS Gene Mutations in Metastatic Colorectal Cancer Patients in Kermanshah Province.	Asian Pac J Cancer Prev	2016	Amirifard N	-
24055406	Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning.	Respir Med	2013 Nov	Hosgood HD 3rd	doi: 10.1016/j.rmed.2013.08.018
18676835	Loss of integrin alpha1beta1 ameliorates Kras-induced lung cancer.	Cancer Res	2008 Aug 1	Macias-Perez I	doi: 10.1158/0008-5472.CAN-08-1395.
19603018	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.	Br J Cancer	2009 Aug 18	Loupakis F	doi: 10.1038/sj.bjc.6605177
17172815	Knockdown of mutant K-ras expression by adenovirus-mediated siRNA inhibits the in vitro and in vivo growth of lung cancer cells.	Cancer Biol Ther	2006 Nov	Zhang Z	-
20372787	KRAS mutations in Slovene patients with colorectal cancer: frequency, distribution and correlation with the response to treatment.	Int J Oncol	2010 May	Licar A	-
22383492	Oncogenic KRAS regulates BMP4 expression in colon cancer cell lines.	Am J Physiol Gastrointest Liver Physiol	2012 May 15	Duerr EM	doi: 10.1152/ajpgi.00047.2011
23511561	KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: results from a large international multicentre study.	Br J Cancer	2013 Apr 16	van Grieken NC	doi: 10.1038/bjc.2013.109
24798549	Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan.	Oncotarget	2014 May 15	Maitra R	-
26829579	Detection of KRAS mutations using double-stranded toehold-exchange probes.	Biosens Bioelectron	2016 Jun 15	Wu Z	doi: 10.1016/j.bios.2016.01.055
17697521	No duplicate KRAS mutation is identified on the same allele in gastric or colorectal cancer cells with multiple KRAS mutations.	J Int Med Res	2007 Jul-Aug	Kimura K	-
23864308	KRAS mutations and rectal cancer response to chemoradiation: are we closer to personalization of therapy?	Ann Surg Oncol	2013 Oct	Krishnan S	doi: 10.1245/s10434-013-3107-2
19238210	Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.	PLoS One	2009	Gandhi J	doi: 10.1371/journal.pone.0004576
22770374	Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype.	Lung Cancer	2012 Oct	Metro G	doi: 10.1016/j.lungcan.2012.06.005
23817662	Application of PCR methods to evaluate EGFR, KRAS and BRAF mutations in a small number of tumor cells in cytological material from lung cancer patients.	Oncol Rep	2013 Sep	Lewandowska MA	doi: 10.3892/or.2013.2579
22701724	Deregulated miRNAs in hereditary breast cancer revealed a role for miR-30c in regulating KRAS oncogene.	PLoS One	2012	Tanic M	doi: 10.1371/journal.pone.0038847
19018267	KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.	Br J Cancer	2008 Dec 16	Nakayama N	doi: 10.1038/sj.bjc.6604783
24398677	Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer.	J Biol Chem	2014 Feb 14	Kahlert C	doi: 10.1074/jbc.C113.532267
24505265	Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients.	PLoS One	2014 Feb 4	Lin YL	doi: 10.1371/journal.pone.0086789
23510802	KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.	Eur J Cancer	2013 Jul	Smith JC	doi: 10.1016/j.ejca.2013.02.023
22341439	TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers.	Cell	2012 Feb 17	Singh A	doi: 10.1016/j.cell.2011.12.033.
27008036	Chronic Obstructive Pulmonary Disease Is Not Associated with KRAS Mutations in Non-Small Cell Lung Cancer.	PLoS One	2016 Mar 23	Saber A	doi: 10.1371/journal.pone.0152317
21129603	Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer.	Cancer Treat Rev	2010 Nov	Sartore-Bianchi A	doi: 10.1016/S0305-7372(10)70012-8.
25911860	K-Ras mutation and prognosis of colorectal cancer: a meta-analysis.	Hepatogastroenterology	2015 Jan-Feb	Rui Y	-
17192038	Detection of a K-ras mutation in urine of patients with colorectal cancer.	Cancer Biomark	2005	Su YH	-
23174662	KRAS above and beyond - EGFR in pancreatic cancer.	Oncotarget	2012 Nov	Siveke JT	-
20592359	Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors.	Anticancer Res	2010 May	Benesova L	-
19179548	The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.	Ann Oncol	2009 May	Garm Spindler KL	doi: 10.1093/annonc/mdn712
23473635	KRAS mutation does not predict the efficacy of neo-adjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis.	Surg Oncol	2013 Jun	Clancy C	doi: 10.1016/j.suronc.2013.02.001
24659028	Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.	Int J Cancer	2014 Nov 1	Spindler KL	doi: 10.1002/ijc.28863
19164213	Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.	J Clin Oncol	2009 Mar 1	Bibeau F	doi: 10.1200/JCO.2008.18.0463
23280667	Caveolin-1 is a novel regulator of K-RAS-dependent migration in colon carcinogenesis.	Int J Cancer	2013 Jul	Basu Roy UK	doi: 10.1002/ijc.28001
21271222	KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.	Oncol Rep	2011 Apr	Kurtze I	doi: 10.3892/or.2011.1160
21962894	Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer.	Cancer Genet	2011 Aug	Pinto P	doi: 10.1016/j.cancergen.2011.07.003.
26209642	Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.	Ann Oncol	2015 Oct	Rulli E	doi: 10.1093/annonc/mdv318
23370967	Ras inhibition enhances autophagy, which partially protects cells from death.	Oncotarget	2013 Jan	Schmukler E	-
24463346	The clinical relevance of KRAS gene mutation in non-small-cell lung cancer.	Curr Opin Oncol	2014 Mar	Timar J	doi: 10.1097/CCO.0000000000000051.
17449174	Origin and prognostic value of circulating KRAS mutations in lung cancer patients.	Cancer Lett	2007 Sep 8	Gautschi O	-
24954536	KRAS and YAP1 converge to regulate EMT and tumor survival.	Cell	2014 Jul 3	Shao DD	doi: 10.1016/j.cell.2014.06.004
15112354	Detection of K-ras point mutation and telomerase activity during endoscopic retrograde cholangiopancreatography in diagnosis of pancreatic cancer.	World J Gastroenterol	2004 May 1	Zhou GX	-
23033302	KRAS and BRAF mutations in Serbian patients with colorectal cancer.	J BUON	2012 Jul-Sep	Jakovljevic K	-
23865079	Loss of RASSF1A expression in colorectal cancer and its association with K-ras status.	Biomed Res Int	2013	Cao D	doi: 10.1155/2013/976765
16158056	Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer.	Oncogene	2006 Jan 5	Seiden-Long IM	-
26515332	KRAS polymorphisms are associated with survival of CRC in Chinese population.	Tumour Biol	2016 Apr	Dai Q	doi: 10.1007/s13277-015-4314-1
21737635	Estimating preclinical efficacy targets utilizing cetuximab efficacy in KRAS mutant and wild-type colorectal cancer models.	Anticancer Res	2011 Jun	Prewett M	-
23640097	The prevalence and prognostic significance of KRAS mutation in bladder cancer, chronic myeloid leukemia and colorectal cancer.	Mol Biol Rep	2013 Jun	Ouerhani S	doi: 10.1007/s11033-013-2512-8
22446022	Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.	Eur J Cancer	2012 Jul	Bokemeyer C	doi: 10.1016/j.ejca.2012.02.057
22864777	Clinical-pathological correlation of K-Ras mutation and ERK phosphorylation in colorectal cancer.	Pol J Pathol	2012 Jun	Tai CJ	-
20718705	KRAS mutation testing of colorectal cancer for anti-EGFR therapy: dogmas versus evidence.	Curr Cancer Drug Targets	2010 Dec	Timar J	-
24952473	Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells.	Oncotarget	2014 Jul 15	Brunelli L	-
19056857	High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.	Oncologist	2008 Dec	Santini D	doi: 10.1634/theoncologist.2008-0181
23015072	KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines.	J Cancer Res Clin Oncol	2013 Feb	Messner I	doi: 10.1007/s00432-012-1319-7
20959826	KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis.	Br J Cancer	2010 Nov 9	Deschoolmeester V	doi: 10.1038/sj.bjc.6605959
25167228	KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.	Br J Cancer	2014 Oct 28	Hamidi H	doi: 10.1038/bjc.2014.475
21994416	A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.	Clin Cancer Res	2011 Dec 15	Smits KM	doi: 10.1158/1078-0432.CCR-11-0990
22579930	Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population.	Clin Chim Acta	2012 Oct 9	Hsieh LL	doi: 10.1016/j.cca.2012.04.029
21876563	Detection of KRAS gene mutations in endoscopic ultrasound-guided fine-needle aspiration biopsy for improving pancreatic cancer diagnosis.	Am J Gastroenterol	2011 Dec	Wang X	doi: 10.1038/ajg.2011.281
19545448	A novel method, digital genome scanning detects KRAS gene amplification in gastric cancers: involvement of overexpressed wild-type KRAS in downstream signaling and cancer cell growth.	BMC Cancer	2009 Jun 23	Mita H	doi: 10.1186/1471-2407-9-198.
26026309	Discrepancies between the K-ras mutational status of primary colorectal cancers and corresponding liver metastases are found in codon 13.	Genomics	2015 Aug	Kawamata H	doi: 10.1016/j.ygeno.2015.05.007
23790176	Cetuximab plus chemotherapy as first-line treatment for metastatic colorectal cancer: effect of KRAS mutation on treatment efficacy in Taiwanese patients.	Neoplasma	2013	Chen MC	doi: 10.4149/neo_2013_073.
23026641	Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy.	Lung Cancer	2012 Dec	Yamaguchi F	doi: 10.1016/j.lungcan.2012.08.014
20583472	K-ras expression--marker of dysplasia and cancer.	Roum Arch Microbiol Immunol	2009 Oct-Dec	Bleotu C	-
27183870	Prognostic significance of K-ras mutations in pancreatic cancer: a meta-analysis.	World J Surg Oncol	2016 May 16	Tao LY	doi: 10.1186/s12957-016-0888-3.
22675430	KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.	PLoS One	2012	Garrido-Laguna I	doi: 10.1371/journal.pone.0038033
24282149	Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels.	Hum Mutat	2014 Feb	Crowley EH	doi: 10.1002/humu.22487
22498935	Molecular characterization of endometrial cancer: a correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis.	Int J Gynecol Pathol	2012 May	Peterson LM	doi: 10.1097/PGP.0b013e318231fc51.
23022742	Intratumoral heterogeneity of KRAS mutation is rare in non-small-cell lung cancer.	Exp Mol Pathol	2013 Feb	Alsdorf WH	doi: 10.1016/j.yexmp.2012.09.016
25884297	Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer.	BMC Cancer	2015 Mar 14	Birgisson H	doi: 10.1186/s12885-015-1144-x.
21468700	Expression of chemokine receptor CCR5 correlates with the presence of hepatic molecular metastases in K-ras positive human colorectal cancer.	J Cancer Res Clin Oncol	2011 Jul	Schimanski CC	doi: 10.1007/s00432-011-0980-6
24642668	Analysis of KRAS mutations in cases of metastatic colorectal cancer at a single institution in Tochigi, Japan.	Pathobiology	2014	Saito N	doi: 10.1159/000357812
26744320	Oncogenic KRAS activates an embryonic stem cell-like program in human colon cancer initiation.	Oncotarget	2016 Jan 19	Le Rolle AF	doi: 10.18632/oncotarget.6818.
23090042	KRAS mutations are associated with specific morphologic features in colon cancer.	J Clin Gastroenterol	2013 Jul	Gunal A	doi: 10.1097/MCG.0b013e3182703030.
19549774	Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.	Clin Cancer Res	2009 Jul 1	Yen LC	doi: 10.1158/1078-0432.CCR-08-3179
25359494	Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.	FASEB J	2015 Feb	Alamo P	doi: 10.1096/fj.14-262303
24720724	KRAS mutations: variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients.	BMC Gastroenterol	2014 Apr 10	Gil Ferreira C	doi: 10.1186/1471-230X-14-73.
26600545	Study of PIK3CA, BRAF, and KRAS mutations in breast carcinomas among Chinese women in Qinghai.	Genet Mol Res	2015 Nov 23	Wang YL	doi: 10.4238/2015.November.18.49.
20845292	Genetic aberrations of the K-ras proto-oncogene in bladder cancer in Kashmiri population.	Urol J	2010 Summer	Nanda MS	-
24906690	Relationships between KRAS mutation status and baseline radiographic distribution of disease in patients with stage IV colorectal cancer.	Abdom Imaging	2014 Dec	Rosenthal MH	doi: 10.1007/s00261-014-0165-2.
26887348	The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis.	BMC Cancer	2016 Feb 18	Kim HS	doi: 10.1186/s12885-016-2141-4.
25086186	Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH.	Cancer Lett	2014 Oct 28	Das K	doi: 10.1016/j.canlet.2014.07.021
26799184	Comparison of liver oncogenic potential among human RAS isoforms.	Oncotarget	2016 Feb 9	Chung SI	doi: 10.18632/oncotarget.6931.
21109984	Tissue sampling for mutation analysis in colorectal cancer: K-ras is homogeneously distributed throughout the tumor tissue.	Oncol Rep	2011 Jan	Ekelund S	-
26710843	Impact of KRAS variant rs61764370 on breast cancer morbidity.	Exp Oncol	2015 Dec	Ustinova M	-
21228335	Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.	Ann Oncol	2011 Jul	Bokemeyer C	doi: 10.1093/annonc/mdq632
15741570	Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.	J Natl Cancer Inst	2005 Mar 2	Shigematsu H	-
23723075	HDAC6 and SIRT2 regulate the acetylation state and oncogenic activity of mutant K-RAS.	Mol Cancer Res	2013 Sep	Yang MH	doi: 10.1158/1541-7786.MCR-13-0040-T
23208128	KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy.	Ann Surg Oncol	2013 Apr	Guan JL	doi: 10.1245/s10434-012-2754-z
23729275	A let-7 binding site polymorphism rs712 in the KRAS 3' UTR is associated with an increased risk of gastric cancer.	Tumour Biol	2013 Oct	Li ZH	doi: 10.1007/s13277-013-0885-x
27064574	Heterogeneity of KRAS Mutation Status in Rectal Cancer.	PLoS One	2016 Apr 11	Jo P	doi: 10.1371/journal.pone.0153278
26520779	[KRAS and bronchial adenocarcinoma. Between disappointments and hopes].	Rev Mal Respir	2016 Feb	Guibert N	doi: 10.1016/j.rmr.2015.05.012
23874486	Colorectal cancer patients with low abundance of KRAS mutation may benefit from EGFR antibody therapy.	PLoS One	2013 Jul 9	Yu S	doi: 10.1371/journal.pone.0068022
24648348	EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation.	Cancer Res	2014 May 15	Wang M	doi: 10.1158/0008-5472.CAN-13-3157
25201577	Association between a functional polymorphism rs712 within let-7-binding site and risk of papillary thyroid cancer.	Med Oncol	2014 Oct	Jin H	doi: 10.1007/s12032-014-0221-3
22810479	Is K-ras gene mutation a prognostic factor for colorectal cancer: a systematic review and meta-analysis.	Dis Colon Rectum	2012 Aug	Ren J	doi: 10.1097/DCR.0b013e318251d8d9.
26842935	Aurora kinase targeting in lung cancer reduces KRAS-induced transformation.	Mol Cancer	2016 Feb 3	Dos Santos EO	doi: 10.1186/s12943-016-0494-6.
24935174	Whole genome gene copy number profiling of gastric cancer identifies PAK1 and KRAS gene amplification as therapy targets.	Genes Chromosomes Cancer	2014 Nov	Qian Z	doi: 10.1002/gcc.22196
23021375	EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.	Discov Med	2012 Sep	Berg M	-
21097396	[Construction of let-7a expression plasmid and its inhibitory effect on k-Ras protein in A549 lung cancer cells].	Nan Fang Yi Ke Da Xue Xue Bao	2010 Nov	He XY	-
26028026	Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP.	Oncogene	2016 Mar 10	Ricoult SJ	doi: 10.1038/onc.2015.179
12032847	K-ras mutations and RASSF1A promoter methylation in colorectal cancer.	Oncogene	2002 May 23	van Engeland M	-
17632319	Lifetime history of tobacco consumption and K-ras mutations in exocrine pancreatic cancer.	Pancreas	2007 Aug	Crous-Bou M	-
23455880	KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.	J Cancer Res Clin Oncol	2013 Jun	Modest DP	doi: 10.1007/s00432-013-1401-9
21383284	Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.	J Clin Oncol	2011 Apr 1	Hutchins G	doi: 10.1200/JCO.2010.30.1366
23613396	The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.	J BUON	2013 Jan-Mar	Selcukbiricik F	-
26275461	Hsa-miR-1 suppresses breast cancer development by down-regulating K-ras and long non-coding RNA MALAT1.	Int J Biol Macromol	2015 Nov	Liu R	doi: 10.1016/j.ijbiomac.2015.08.016
17130841	Oncogenic K-RAS subverts the antiapoptotic role of N-RAS and alters modulation of the N-RAS:gelsolin complex.	Oncogene	2007 May 10	Keller JW	-
15923430	Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study.	Ann Oncol	2005 May	Bazan V	-
25688918	KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer.	Br J Cancer	2015 Feb 17	Renaud S	doi: 10.1038/bjc.2014.499.
23374602	Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.	BMC Cancer	2013 Feb 2	Pentheroudakis G	doi: 10.1186/1471-2407-13-49.
21150464	Evaluation of Kras gene mutation and copy number gain in non-small cell lung cancer.	J Thorac Oncol	2011 Jan	Sasaki H	doi: 10.1097/JTO.0b013e31820594f0.
24407191	Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.	Br J Cancer	2014 Mar 4	Samalin E	doi: 10.1038/bjc.2013.813
24595598	EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.	J Cancer Res Clin Oncol	2014 May	Razis E	doi: 10.1007/s00432-014-1626-2
24244261	Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer.	PLoS One	2013 Nov 11	Siena S	doi: 10.1371/journal.pone.0062264
23787801	KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.	J Thorac Oncol	2013 Sep	Mellema WW	doi: 10.1097/JTO.0b013e318298764e.
23999847	K-RAS mutation profile in Puerto Rican patients with colorectal cancer: trends from April 2009 to January 2011.	Int J Biol Markers	2013 Dec 17	Ruiz-Candelaria Y	doi: 10.5301/JBM.5000043.
20842128	Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy.	Br J Cancer	2010 Sep 28	Bengala C	doi: 10.1038/sj.bjc.6605853
25961464	Estrogen withdrawal, increased breast cancer risk and the KRAS-variant.	Cell Cycle	2015	McVeigh TP	doi: 10.1080/15384101.2015.1041694
19881948	BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells.	Neoplasia	2009 Nov	Oikonomou E	-
16448675	Polymorphisms in insulin-related genes predispose to specific KRAS2 and TP53 mutations in colon cancer.	Mutat Res	2006 Mar 20	Samowitz WS	-
19190129	Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans.	Clin Cancer Res	2009 Feb 15	Kumar K	doi: 10.1158/1078-0432.CCR-08-1029
23288781	Targeted degradation of KRAS by an engineered ubiquitin ligase suppresses pancreatic cancer cell growth in vitro and in vivo.	Mol Cancer Ther	2013 Mar	Ma Y	doi: 10.1158/1535-7163.MCT-12-0650
20610624	miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer.	Cancer Res	2010 Jul 15	Yu S	doi: 10.1158/0008-5472.CAN-09-4531
25065594	Differential in vivo tumorigenicity of diverse KRAS mutations in vertebrate pancreas: A comprehensive survey.	Oncogene	2015 May 21	Park JT	doi: 10.1038/onc.2014.223
26775732	Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.	Crit Rev Oncol Hematol	2016 Mar	Passiglia F	doi: 10.1016/j.critrevonc.2015.12.015
26563370	Emerging prognostic markers related to mesenchymal characteristics of poorly differentiated breast cancers.	Tumour Biol	2016 Apr	Scimeca M	doi: 10.1007/s13277-015-4361-7
23538866	KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making.	Am J Clin Oncol	2015 Feb	Campos-Parra AD	doi: 10.1097/COC.0b013e318287bb23.
28000889	High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases.	Oncol Rep	2017 Feb	Fujiyoshi K	doi: 10.3892/or.2016.5323
28489996	Cancer-Associated Mutations in Endometriosis without Cancer.	N Engl J Med	2017 May 11	Anglesio MS	doi: 10.1056/NEJMoa1614814.
25902737	Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer.	Clin Exp Med	2016 May	Nicos M	doi: 10.1007/s10238-015-0349-2
27444698	Prognostic relevance of autophagy-related markers LC3, p62/sequestosome 1, Beclin-1 and ULK1 in colorectal cancer patients with respect to KRAS mutational status.	World J Surg Oncol	2016 Jul 22	Schmitz KJ	doi: 10.1186/s12957-016-0946-x.
28233357	Promotion of invasion by mutant RAS is dependent on activation of the WASF3 metastasis promoter gene.	Genes Chromosomes Cancer	2017 Jun	Teng Y	doi: 10.1002/gcc.22453
27737491	Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases.	Cancer	2017 Feb 15	Frankel TL	doi: 10.1002/cncr.30351
27225938	K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis.	Med Oncol	2016 Jul	Li T	doi: 10.1007/s12032-016-0777-1
28074351	KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma.	Med Oncol	2017 Feb	Cicenas J	doi: 10.1007/s12032-016-0879-9
28000854	Identification of microRNA-487b as a negative regulator of liver metastasis by regulation of KRAS in colorectal cancer.	Int J Oncol	2017 Feb	Hata T	doi: 10.3892/ijo.2016.3813
27237100	A meta-analysis of the diagnostic value of detecting K-ras mutation in pancreatic juice as a molecular marker for pancreatic cancer.	Pancreatology	2016 Jul-Aug	Yang J	doi: 10.1016/j.pan.2016.04.033
27343315	Chromosome aberrations [dup(1q)] in endometrial cancer: Gene analysis of 54 surgical specimens in Turkey.	Taiwan J Obstet Gynecol	2016 Jun	Sever E	doi: 10.1016/j.tjog.2016.02.012.
28314302	KRAS Mutant Status May Be Associated with Distant Recurrence in Early-stage Rectal Cancer.	Anticancer Res	2017 Mar	Sideris M	-
28006055	Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.	JAMA Oncol	2017 Apr 1	Sinicrope FA	doi: 10.1001/jamaoncol.2016.5469.
28208157	Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer.	Br J Cancer	2017 Mar 28	Jones RP	doi: 10.1038/bjc.2017.37
27999344	EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer.	Int J Mol Sci	2016 Dec 18	Tomasini P	doi: 10.3390/ijms17122132.
27451147	SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.	Gastroenterology	2016 Nov	Wong CC	doi: 10.1053/j.gastro.2016.07.011
27906963	LncRNA-RMRP Acts as an Oncogene in Lung Cancer.	PLoS One	2016 Dec 1	Meng Q	doi: 10.1371/journal.pone.0164845
28202657	Deciphering the RAS/ERK pathway in vivo.	Biochem Soc Trans	2017 Feb 8	Dorard C	doi: 10.1042/BST20160135.
27698189	miR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3.	Cancer Res	2016 Oct 1	Zhou Y	-
28154181	USP39 Deubiquitinase Is Essential for KRAS Oncogene-driven Cancer.	J Biol Chem	2017 Mar 10	Fraile JM	doi: 10.1074/jbc.M116.762757
26808395	Clinicopathological, endoscopic, and molecular characteristics of the skirt - a new entity of lesions at the margin of laterally spreading tumors.	Endoscopy	2016 May	Osera S	doi: 10.1055/s-0041-111565
26945839	A Crosstalk Between K ras (Kirsten Rat Sarcoma Viral Oncogene Homologue) and Adherence Molecular Complex Leads to Disassociation of Cells-A Possible Contribution Towards Metastasis in Colorectal Cancer.	J Cell Biochem	2016 Oct	Murtaza BN	doi: 10.1002/jcb.25531
27530493	Epidermal growth factor receptor and v-Ki-ras2 Kirsten rat sarcoma viral oncogen homologue-specific amino acid substitutions are associated with different histopathological prognostic factors in resected non-small-cell lung cancer.	Interact Cardiovasc Thorac Surg	2016 Dec	Seitlinger J	-
28453411	Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.	J Clin Oncol	2017 Jun 20	Shepherd FA	doi: 10.1200/JCO.2016.71.2893
28152508	KRAS-dependent suppression of MYC enhances the sensitivity of cancer cells to cytotoxic agents.	Oncotarget	2017 Mar 14	Ischenko I	doi: 10.18632/oncotarget.14929.
27753016	Screening of KRAS Mutation in Pre- and Post-Surgery Serum of Patients Suffering from Colon Cancer by COLD-PCR HRM.	Adv Exp Med Biol	2016	Trujillo-Arribas E	-
28099923	Significant association between Let-7-KRAS rs712 G > T polymorphism and cancer risk in the Chinese population: a meta-analysis.	Oncotarget	2017 Feb 21	Du XY	doi: 10.18632/oncotarget.14672.
28636636	SensiScreenKRAS exon 2-sensitive simplex and multiplex real-time PCR-based assays for detection of KRAS exon 2 mutations.	PLoS One	2017 Jun 21	Riva A	doi: 10.1371/journal.pone.0178027
28576749	A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.	Cancer Lett	2017 Aug 28	Zhao X	doi: 10.1016/j.canlet.2017.05.015
28858102	Prognostic value of KRAS codon 13 gene mutation for overall survival in colorectal cancer: Direct and indirect comparison meta-analysis.	Medicine (Baltimore)	2017 Sep	Kwak MS	doi: 10.1097/MD.0000000000007882.
28796802	The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis.	PLoS One	2017 Aug 10	Zhuang R	doi: 10.1371/journal.pone.0182562
28077799	KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis.	Oncotarget	2017 Mar 28	Du L	doi: 10.18632/oncotarget.14549.
28538732	CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells.	Nature	2017 Jun 1	Kim J	doi: 10.1038/nature22359
27156442	Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma.	J Thorac Oncol	2016 Aug	Lococo F	doi: 10.1016/j.jtho.2016.04.020
27607580	Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.	Cell Death Dis	2016 Sep 8	Klingbeil O	doi: 10.1038/cddis.2016.271.
28899783	Induced sensitivity to EGFR inhibitors is mediated by palmitoylated cysteine 1025 of EGFR and requires oncogenic Kras.	Biochem Biophys Res Commun	2017 Nov 4	Kharbanda A	doi: 10.1016/j.bbrc.2017.09.044
28068936	Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.	BMC Cancer	2017 Jan 9	Nakayama I	doi: 10.1186/s12885-016-2994-6.
27807105	-	-	-	-	-
28859058	Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations.	Br J Cancer	2017 Oct 24	Gollins S	doi: 10.1038/bjc.2017.294
28007627	Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).	J Thorac Oncol	2017 Apr	Schmid S	doi: 10.1016/j.jtho.2016.12.003
27215184	KRas, ROS and the initiation of pancreatic cancer.	Small GTPases	2017 Jan 2	Storz P	doi: 10.1080/21541248.2016.1192714
28249840	New Guideline on Managing Colorectal Cancer.	Cancer Discov	2017 Apr	-	doi: 10.1158/2159-8290.CD-NB2017-030
28846180	Synergistic activity of sorafenib and betulinic acid against clonogenic activity of non-small cell lung cancer cells.	Cancer Sci	2017 Nov	Kutkowska J	doi: 10.1111/cas.13386
26989027	Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.	Oncotarget	2016 Apr 19	Hsu HC	doi: 10.18632/oncotarget.8076.
27012422	L-Ascorbic acid can abrogate SVCT-2-dependent cetuximab resistance mediated by mutant KRAS in human colon cancer cells.	Free Radic Biol Med	2016 Jun	Jung SA	doi: 10.1016/j.freeradbiomed.2016.03.009
28967920	Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.	Nat Med	2017 Nov	Romero R	doi: 10.1038/nm.4407
27468967	Association of KRAS gene mutations with depression in older metastatic colorectal cancer patients.	Int Psychogeriatr	2016 Dec	Zhou Y	-
27835580	KY1022, a small molecule destabilizing Ras via targeting the Wnt/β-catenin pathway, inhibits development of metastatic colorectal cancer.	Oncotarget	2016 Dec 6	Cho YH	doi: 10.18632/oncotarget.13172.
27602501	Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.	Oncotarget	2016 Oct 18	Fernandes MS	doi: 10.18632/oncotarget.11843.
26786089	KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion.	Ann Surg Oncol	2016 Jun	Shindoh J	doi: 10.1245/s10434-016-5087-5
27435400	IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells.	Clin Cancer Res	2017 Jan 15	McMichael EL	doi: 10.1158/1078-0432.CCR-16-0004
27769041	MiR-384 inhibits human colorectal cancer metastasis by targeting KRAS and CDC42.	Oncotarget	2016 Dec 20	Wang YX	doi: 10.18632/oncotarget.12704.
28030835	Co-targeting translation and proteasome rapidly kills colon cancer cells with mutant RAS/RAF via ER stress.	Oncotarget	2017 Feb 7	Li X	doi: 10.18632/oncotarget.14063.
28032595	Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.	Oncotarget	2017 Jan 31	Rouhi A	doi: 10.18632/oncotarget.13841.
26992209	Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers.	Oncotarget	2016 Apr 26	Lee B	doi: 10.18632/oncotarget.8074.
27020587	KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.	Ann Surg Oncol	2016 Aug	Chow OS	doi: 10.1245/s10434-016-5205-4
27517152	A recombinantly tailored β-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer.	Oncotarget	2016 Sep 6	Du Y	doi: 10.18632/oncotarget.11170.
27780929	KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.	Oncotarget	2016 Nov 29	Kenessey I	doi: 10.18632/oncotarget.12806.
27705932	KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control.	Oncotarget	2016 Nov 29	Le Calvez-Kelm F	doi: 10.18632/oncotarget.12386.
28167505	Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERK-p90RSK-mTOR Signaling Network.	Mol Cancer Ther	2017 May	Chatterjee S	doi: 10.1158/1535-7163.MCT-16-0677
28289161	Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation.	Mol Cancer Res	2017 Jul	Yamaoka T	doi: 10.1158/1541-7786.MCR-16-0482
27494869	miR-450b-5p induced by oncogenic KRAS is required for colorectal cancer progression.	Oncotarget	2016 Sep 20	Ye YP	doi: 10.18632/oncotarget.11016.
28407465	KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer.	Korean J Intern Med	2017 May	Park S	doi: 10.3904/kjim.2015.299
28583095	The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients.	BMC Cancer	2017 Jun 5	Won DD	doi: 10.1186/s12885-017-3381-7.
28450086	KRAS mutation testing on all non-malignant diagnosis of pancreatic endoscopic ultrasound-guided fine-needle aspiration biopsies improves diagnostic accuracy.	Pathology	2017 Jun	Trisolini E	doi: 10.1016/j.pathol.2016.12.348
28150169	KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer.	Clin Transl Oncol	2017 Jul	Sullivan I	doi: 10.1007/s12094-017-1620-7
27911859	KRAS exon 2 codon 13 mutation is associated with a better prognosis than codon 12 mutation following lung metastasectomy in colorectal cancer.	Oncotarget	2017 Jan 10	Renaud S	doi: 10.18632/oncotarget.13697.
28749408	Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer.	Int J Mol Sci	2017 Jul 27	Toda K	doi: 10.3390/ijms18081632.
28677778	Wildtype blocking pcr coupled with internal competitive amplified fragment improved the detection of rare mutation of KRAS.	Mol Med Rep	2017 Sep	Peng J	doi: 10.3892/mmr.2017.6883
28797274	The pattern of KRAS mutations in metastatic colorectal cancer: a retrospective audit from Sri Lanka.	BMC Res Notes	2017 Aug 10	Sirisena ND	doi: 10.1186/s13104-017-2731-5.
28216246	Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis.	Clin Colorectal Cancer	2017 Sep	Tosi F	doi: 10.1016/j.clcc.2017.01.004
28901317	k-RAS mutation and resistance to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in patients with nonsmall cell lung cancer.	J Cancer Res Ther	2017	Zhou B	doi: 10.4103/jcrt.JCRT_468_17.
29093617	Detection of KRAS G12D in colorectal cancer stool by droplet digital PCR.	World J Gastroenterol	2017 Oct 21	Olmedillas-López S	doi: 10.3748/wjg.v23.i39.7087.
29364867	Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes.	Nature	2018 Feb 1	Mueller S	doi: 10.1038/nature25459
29104470	Critical Role of p53 and K-ras in the Diagnosis of Early Colorectal Cancer: a One-year, Single-center Analysis.	Int J Med Sci	2017 Sep 13	Lu HY	doi: 10.7150/ijms.20538
28601386	Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment.	Clin Lung Cancer	2017 Nov	Bordi P	doi: 10.1016/j.cllc.2017.04.013
28544747	K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.	Mol Oncol	2017 Sep	Yeung Y	doi: 10.1002/1878-0261.12078
27892494	Circular RNAs are down-regulated in KRAS mutant colon cancer cells and can be transferred to exosomes.	Sci Rep	2016 Nov 28	Dou Y	doi: 10.1038/srep37982.
29851957	KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex.	PLoS One	2018 May 31	Rao DD	doi: 10.1371/journal.pone.0193644
29610327	Precise characterization of KRAS4b proteoforms in human colorectal cells and tumors reveals mutation/modification cross-talk.	Proc Natl Acad Sci U S A	2018 Apr 17	Ntai I	doi: 10.1073/pnas.1716122115
28685592	Investigation of correlation between mutational status in key EGFR signaling genes and prognosis of stage II colorectal cancer.	Future Oncol	2017 Jul	Li L	doi: 10.2217/fon-2017-0040
29335867	Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?	Eur Radiol	2018 May	Yang L	doi: 10.1007/s00330-017-5146-8
29207158	Overexpression of miR-19a inhibits colorectal cancer angiogenesis by suppressing KRAS expression.	Oncol Rep	2018 Feb	Chen M	doi: 10.3892/or.2017.6110
29764594	[Research Progress of KRAS Mutation in Non-small Cell Lung Cancer].	Zhongguo Fei Ai Za Zhi	2018 May 20	Liu L	doi: 10.3779/j.issn.1009-3419.2018.05.11.
29066722	BCL-XL directly modulates RAS signalling to favour cancer cell stemness.	Nat Commun	2017 Oct 24	Carne Trecesson S	doi: 10.1038/s41467-017-01079-1.
29303908	Progression of Chronic Pancreatitis to Pancreatic Cancer: Is There a Role of Gene Mutations as a Screening Tool?	Pancreas	2018 Feb	Rashid S	doi: 10.1097/MPA.0000000000000975.
30047791	PPARγ-Mediated p21 Induction in Aerodigestive Preneoplastic Cell Lines.	Ann Otol Rhinol Laryngol	2018 Oct	Miller WA	doi: 10.1177/0003489418787833
30037374	[Association between EGFR, ALK and KRAS Gene Status and Synchronous Distant Organ Metastasis in Non-small Cell Lung Cancer].	Zhongguo Fei Ai Za Zhi	2018 Jul 20	Gao G	doi: 10.3779/j.issn.1009-3419.2018.07.06.
29263151	KRAS Oncogenic Signaling Extends beyond Cancer Cells to Orchestrate the Microenvironment.	Cancer Res	2018 Jan 1	Dias Carvalho P	doi: 10.1158/0008-5472.CAN-17-2084
29321082	Long Noncoding RNA ATB Promotes Proliferation, Migration, and Invasion in Bladder Cancer by Suppressing MicroRNA-126.	Oncol Res	2018 Aug 23	Zhai X	doi: 10.3727/096504018X15152072098476
28220783	An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer.	Nat Commun	2017 Feb 21	Vallejo A	doi: 10.1038/ncomms14294.
29068469	BAG3-dependent expression of Mcl-1 confers resistance of mutant KRAS colon cancer cells to the HSP90 inhibitor AUY922.	Mol Carcinog	2018 Feb	Wang CY	doi: 10.1002/mc.22755
28508873	Mutant KRAS promotes malignant pleural effusion formation.	Nat Commun	2017 May 16	Agalioti T	doi: 10.1038/ncomms15205.
29556349	Surface Enhanced Raman Spectroscopy (SERS) for the Multiplex Detection of Braf, Kras, and Pik3ca Mutations in Plasma of Colorectal Cancer Patients.	Theranostics	2018 Feb 12	Li X	doi: 10.7150/thno.22502
30368666	Intratumor heterogeneity and tissue distribution of KRAS mutation in non-small cell lung cancer: implications for detection of mutated KRAS oncogene in exhaled breath condensate.	J Cancer Res Clin Oncol	2019 Jan	Kordiak J	doi: 10.1007/s00432-018-2779-1
29413054	A cross-sectional study examining the expression of splice variants K-RAS4A and K-RAS4B in advanced non-small-cell lung cancer patients.	Lung Cancer	2018 Feb	Aran V	doi: 10.1016/j.lungcan.2017.12.005
30683863	Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients.	Nat Commun	2019 Jan 25	Cafri G	doi: 10.1038/s41467-019-08304-z.
29547736	The presence of KRAS, PPP2R1A and ARID1A mutations in 101 Chinese samples with ovarian endometriosis.	Mutat Res	2018 May	Zou Y	doi: 10.1016/j.mrfmmm.2018.03.001
29116623	KRAS Mutation in Gastric Cancer and Prognostication Associated with Microsatellite Instability Status.	Pathol Oncol Res	2019 Jan	Polom K	doi: 10.1007/s12253-017-0348-6
30599853	Genomics of non-small cell lung cancer (NSCLC): Association between CT-based imaging features and EGFR and K-RAS mutations in 122 patients-An external validation.	Eur J Radiol	2019 Jan	Rizzo S	doi: 10.1016/j.ejrad.2018.11.032
29453361	Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C.	Oncogene	2018 May	Cannataro VL	doi: 10.1038/s41388-017-0105-z
29559746	Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway.	Oncogene	2018 Jun	Chu PC	doi: 10.1038/s41388-018-0222-3
29786130	RAS Mutation is Associated with Unsalvageable Recurrence Following Hepatectomy for Colorectal Cancer Liver Metastases.	Ann Surg Oncol	2018 Aug	Okuno M	doi: 10.1245/s10434-018-6517-3
28043144	Association of EGFR and KRAS mutations with expression of p-AKT, DR5 and DcR1 in non-small cell lung cancer.	Neoplasma	2017	Zhao XD	doi: 10.4149/neo_2017_203.
30467381	Mutant Kras-induced upregulation of CD24 enhances prostate cancer stemness and bone metastasis.	Oncogene	2019 Mar	Weng CC	doi: 10.1038/s41388-018-0575-7
30562355	Analysis of KRAS, NRAS and BRAF mutational profile by combination of in-tube hybridization and universal tag-microarray in tumor tissue and plasma of colorectal cancer patients.	PLoS One	2018 Dec 18	Damin F	doi: 10.1371/journal.pone.0207876
30361395	Positive association of PIK3CA mutation with KRAS mutation but not BRAF mutation in colorectal cancer suggests co-selection is gene specific but not pathway specific.	J Clin Pathol	2019 Mar	Susanti S	doi: 10.1136/jclinpath-2018-205483
29808006	SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.	Nat Med	2018 Jul	Mainardi S	doi: 10.1038/s41591-018-0023-9
29454587	Comparison of CT radiogenomic and clinical characteristics between EGFR and KRAS mutations in lung adenocarcinomas.	Clin Radiol	2018 Jun	Lv J	doi: 10.1016/j.crad.2018.01.009

Expression in 33 cancers

Mutations

Cancer	Chr	Position	Mutation Type	dbSNP	Protein-change	Allele Freq	RBD
BLCA	chr12	25227348	Missense_Mutation	NA	A59G	0.5	GTP_EFTU
BLCA	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.56	GTP_EFTU
BLCA	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.61	GTP_EFTU
BLCA	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.4	GTP_EFTU
BLCA	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.89	GTP_EFTU
BLCA	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.48	GTP_EFTU
BLCA	chr12	25245328	Missense_Mutation	NA	L19F	0.48	GTP_EFTU
BLCA	chr12	25209894	3'UTR	novel		0.56
BLCA	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.43	GTP_EFTU
BLCA	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.71	GTP_EFTU
BLCA	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.77	GTP_EFTU
BLCA	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.49	GTP_EFTU
BLCA	chr12	25245328	Missense_Mutation	NA	L19F	0.27	GTP_EFTU
BLCA	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.28	GTP_EFTU
BLCA	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.78	GTP_EFTU
BLCA	chr12	25227341	Missense_Mutation	rs17851045	Q61H	0.48	GTP_EFTU
BLCA	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.58	GTP_EFTU
BRCA	chr12	25209810	3'UTR	novel		0.39
BRCA	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.13	GTP_EFTU
BRCA	chr12	25209692	3'UTR	novel		0.45
BRCA	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.37	GTP_EFTU
BRCA	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.19	GTP_EFTU
BRCA	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.3	GTP_EFTU
BRCA	chr12	25209569	3'UTR	novel		0.67
BRCA	chr12	25227250	Missense_Mutation	NA	D92Y	0.19	GTP_EFTU
BRCA	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.24	GTP_EFTU
CESC	chr12	25225628	Missense_Mutation	rs121913527	A146T	0.55
CESC	chr12	25208265	3'Flank	novel		0.31
CESC	chr12	25206402	3'Flank	novel		0.71
CESC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.48	GTP_EFTU
CESC	chr12	25245323	Missense_Mutation	NA	I21R	0.47	GTP_EFTU
CESC	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.19	GTP_EFTU
CESC	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.3	GTP_EFTU
CESC	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.16	GTP_EFTU
CESC	chr12	25208682	3'Flank	novel		0.16
CESC	chr12	25245345	Missense_Mutation	rs104894365	V14I	0.45	GTP_EFTU
CESC	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.48	GTP_EFTU
CESC	chr12	25227281	Silent	novel	V81V	0.25
CESC	chr12	25225628	Missense_Mutation	rs121913527	A146T	0.91
CESC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.56	GTP_EFTU
CESC	chr12	25208588	3'Flank	novel		0.63
CESC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.56	GTP_EFTU
CESC	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.18	GTP_EFTU
CESC	chr12	25204851	3'Flank	novel		0.16
CESC	chr12	25205433	3'Flank	novel		0.17
CESC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.47	GTP_EFTU
CESC	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.31	GTP_EFTU
CESC	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.53	GTP_EFTU
CHOL	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.2	GTP_EFTU
CHOL	chr12	25205016	3'Flank	novel		0.24
CHOL	chr12	25227343	Missense_Mutation	rs121913238	Q61K	0.21	GTP_EFTU
CHOL	chr12	25227344	Silent	rs397517037	G60G	0.2
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.47	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.54	GTP_EFTU
COAD	chr12	25227343	Missense_Mutation	rs121913238	Q61K	0.39	GTP_EFTU
COAD	chr12	25227344	Silent	rs397517037	G60G	0.38
COAD	chr12	25227320	Missense_Mutation	NA	R68S	0.31	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.34	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.5	GTP_EFTU
COAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.37	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.34	GTP_EFTU
COAD	chr12	25225713	Missense_Mutation	NA	K117N	0.4	GTP_EFTU
COAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.4	GTP_EFTU
COAD	chr12	25225628	Missense_Mutation	rs121913527	A146T	0.23
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.38	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.43	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.49	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.58	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.43	GTP_EFTU
COAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.29	GTP_EFTU
COAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.36	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.32	GTP_EFTU
COAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.46	GTP_EFTU
COAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.49	GTP_EFTU
COAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.59	GTP_EFTU
COAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.59	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.21	GTP_EFTU
COAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.41	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.36	GTP_EFTU
COAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.52	GTP_EFTU
COAD	chr12	25227342	Missense_Mutation	rs121913240	Q61R	0.37	GTP_EFTU
COAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.39	GTP_EFTU
COAD	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.62	GTP_EFTU
COAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.12	GTP_EFTU
COAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.89	GTP_EFTU
COAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.58	GTP_EFTU
COAD	chr12	25245348	Missense_Mutation	rs121913535	G13C	0.35	GTP_EFTU
COAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.2	GTP_EFTU
COAD	chr12	25225628	Missense_Mutation	rs121913527	A146T	0.38
COAD	chr12	25209700	3'UTR	novel		0.15
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.13	GTP_EFTU
COAD	chr12	25225713	Missense_Mutation	rs770248150	K117N	0.26	GTP_EFTU
COAD	chr12	25245321	Missense_Mutation	rs121913236	Q22K	0.26	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.45	GTP_EFTU
COAD	chr12	25225627	Missense_Mutation	NA	A146V	0.32
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.38	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.58	GTP_EFTU
COAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.34	GTP_EFTU
COAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.49	GTP_EFTU
COAD	chr12	25245351	Missense_Mutation	rs121913530	G12S	0.63	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.33	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.27	GTP_EFTU
COAD	chr12	25225628	Missense_Mutation	rs121913527	A146T	0.83
COAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.22	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.41	GTP_EFTU
COAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.4	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.2	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.68	GTP_EFTU
COAD	chr12	25245351	Missense_Mutation	rs121913530	G12S	0.2	GTP_EFTU
COAD	chr12	25245351	Missense_Mutation	rs121913530	G12S	0.71	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.71	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.33	GTP_EFTU
COAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.39	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.28	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.54	GTP_EFTU
COAD	chr12	25225628	Missense_Mutation	rs121913527	A146T	0.23
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.22	GTP_EFTU
COAD	chr12	25225628	Missense_Mutation	rs121913527	A146T	0.32
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.16	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.45	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.37	GTP_EFTU
COAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.47	GTP_EFTU
COAD	chr12	25245351	Missense_Mutation	rs121913530	G12S	0.23	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.45	GTP_EFTU
COAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.65	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.45	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.58	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.2	GTP_EFTU
COAD	chr12	25225628	Missense_Mutation	rs121913527	A146T	0.62
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.46	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.55	GTP_EFTU
COAD	chr12	25209786	3'UTR	novel		0.15
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.32	GTP_EFTU
COAD	chr12	25227342	Missense_Mutation	rs121913240	Q61R	0.39	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.12	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.41	GTP_EFTU
COAD	chr12	25227341	Missense_Mutation	rs17851045	Q61H	0.4	GTP_EFTU
COAD	chr12	25227343	Missense_Mutation	rs121913238	Q61K	0.53	GTP_EFTU
COAD	chr12	25227344	Silent	NA	G60G	0.52
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.38	GTP_EFTU
COAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.46	GTP_EFTU
COAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.25	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.37	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.37	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.6	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.28	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.36	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.49	GTP_EFTU
COAD	chr12	25245351	Missense_Mutation	rs121913530	G12S	0.86	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.36	GTP_EFTU
COAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.4	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.27	GTP_EFTU
COAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.4	GTP_EFTU
COAD	chr12	25227343	Missense_Mutation	rs121913238	Q61K	0.17	GTP_EFTU
COAD	chr12	25227344	Silent	rs397517037	G60G	0.18
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.15	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.47	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.38	GTP_EFTU
COAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.76	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.5	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.38	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.49	GTP_EFTU
COAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.38	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.55	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.62	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.43	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.42	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.76	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.57	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.34	GTP_EFTU
COAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.19	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.41	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.28	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.61	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.36	GTP_EFTU
COAD	chr12	25225628	Missense_Mutation	rs121913527	A146T	0.17
COAD	chr12	25215547	Missense_Mutation	NA	A155D	0.35
COAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.5	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.63	GTP_EFTU
COAD	chr12	25245348	Missense_Mutation	rs121913535	G13C	0.19	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.33	GTP_EFTU
COAD	chr12	25245328	Missense_Mutation	NA	L19F	0.19	GTP_EFTU
COAD	chr12	25225628	Missense_Mutation	rs121913527	A146T	0.45
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.44	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.41	GTP_EFTU
COAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.96	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.4	GTP_EFTU
COAD	chr12	25225713	Missense_Mutation	NA	K117N	0.46	GTP_EFTU
COAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.3	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.51	GTP_EFTU
COAD	chr12	25245351	Missense_Mutation	rs121913530	G12S	0.41	GTP_EFTU
COAD	chr12	25225628	Missense_Mutation	rs121913527	A146T	0.28
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.36	GTP_EFTU
COAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.42	GTP_EFTU
COAD	chr12	25225713	Missense_Mutation	rs770248150	K117N	0.56	GTP_EFTU
COAD	chr12	25245284	Missense_Mutation	rs104894366	P34L	0.18	GTP_EFTU
COAD	chr12	25225628	Missense_Mutation	rs121913527	A146T	0.46
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.35	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.84	GTP_EFTU
COAD	chr12	25209730	3'UTR	novel		0.36
COAD	chr12	25209871	3'UTR	rs372793780		0.31
COAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.54	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.79	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.36	GTP_EFTU
COAD	chr12	25227341	Missense_Mutation	rs17851045	Q61H	0.39	GTP_EFTU
COAD	chr12	25209692	3'UTR	novel		0.33
COAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.49	GTP_EFTU
COAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.76	GTP_EFTU
COAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.17	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.3	GTP_EFTU
COAD	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.27	GTP_EFTU
COAD	chr12	25215550	Nonsense_Mutation	novel	*D154Vfs4**	0.04
COAD	chr12	25215551	Missense_Mutation	novel	D154N	0.01
COAD	chr12	25225628	Missense_Mutation	rs121913527	A146T	0.7
COAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.51	GTP_EFTU
COAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.47	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.58	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.23	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.32	GTP_EFTU
COAD	chr12	25225628	Missense_Mutation	rs121913527	A146T	0.81
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.35	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.42	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.22	GTP_EFTU
COAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.5	GTP_EFTU
COAD	chr12	25245351	Missense_Mutation	rs121913530	G12S	0.41	GTP_EFTU
DLBC	chr12	25245321	Missense_Mutation	rs121913236	Q22K	0.61	GTP_EFTU
DLBC	chr12	25245328	Missense_Mutation	rs121913538	L19F	0.24	GTP_EFTU
ESCA	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.32	GTP_EFTU
ESCA	chr12	25209273	3'Flank	novel		0.48
ESCA	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.29	GTP_EFTU
GBM	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.26	GTP_EFTU
GBM	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.59	GTP_EFTU
HNSC	chr12	25215539	Missense_Mutation	NA	T158A	0.06
HNSC	chr12	25209701	3'UTR	novel		0.54
KIRC	chr12	25227348	Missense_Mutation	NA	A59G	0.11	GTP_EFTU
KIRP	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.51	GTP_EFTU
KIRP	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.35	GTP_EFTU
KIRP	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.32	GTP_EFTU
KIRP	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.66	GTP_EFTU
KIRP	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.52	GTP_EFTU
LAML	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.63	GTP_EFTU
LAML	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.19	GTP_EFTU
LAML	chr12	25227341	Missense_Mutation	rs17851045	Q61H	0.14	GTP_EFTU
LAML	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.18	GTP_EFTU
LAML	chr12	25245277	Missense_Mutation	rs727503109	I36M	0.61	GTP_EFTU
LAML	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.47	GTP_EFTU
LAML	chr12	25227348	Missense_Mutation	NA	A59E	0.39	GTP_EFTU
LGG	chr12	25245346	Silent	rs397517040	G13G	0.2
LGG	chr12	25245372	Missense_Mutation	rs193929331	K5E	0.4
LIHC	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.35	GTP_EFTU
LIHC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.47	GTP_EFTU
LIHC	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.47	GTP_EFTU
LIHC	chr12	25209860	3'UTR	novel		0.35
LIHC	chr12	25227321	Missense_Mutation	NA	R68M	0.22	GTP_EFTU
LIHC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.15	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.55	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.2	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.44	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.35	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.3	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.29	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.95	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.35	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.47	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.32	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.43	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.28	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.22	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.31	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.11	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.19	GTP_EFTU
LUAD	chr12	25227262	Nonsense_Mutation	NA	K88*	0.24	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.41	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.21	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.61	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.44	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.57	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.5	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.32	GTP_EFTU
LUAD	chr12	25227342	Missense_Mutation	rs121913240	Q61L	0.8	GTP_EFTU
LUAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.45	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.43	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.23	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.8	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.63	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.46	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.19	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.25	GTP_EFTU
LUAD	chr12	25245348	Missense_Mutation	rs121913535	G13C	0.57	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.3	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.39	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.44	GTP_EFTU
LUAD	chr12	25227342	Missense_Mutation	rs121913240	Q61L	0.16	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.61	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.36	GTP_EFTU
LUAD	chr12	25245348	Missense_Mutation	rs121913535	G13C	0.2	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.22	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.22	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.39	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.4	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.3	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.32	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.34	GTP_EFTU
LUAD	chr12	25245328	Missense_Mutation	rs121913538	L19F	0.26	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.74	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12S	0.28	GTP_EFTU
LUAD	chr12	25225628	Missense_Mutation	NA	A146P	0.81
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.36	GTP_EFTU
LUAD	chr12	25245328	Missense_Mutation	NA	L19F	0.6	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.23	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.52	GTP_EFTU
LUAD	chr12	25245348	Missense_Mutation	rs121913535	G13C	0.6	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.09	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.29	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.27	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.39	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.38	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.44	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12S	0.33	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.58	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.5	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.17	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.37	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.67	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.21	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.23	GTP_EFTU
LUAD	chr12	25245286	Missense_Mutation	NA	D33E	0.35	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.28	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.29	GTP_EFTU
LUAD	chr12	25245348	Missense_Mutation	rs121913535	G13C	0.71	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.6	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.6	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.81	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.61	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.29	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.26	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.13	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12S	0.71	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.57	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.2	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.41	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12S	0.41	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.57	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.22	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.19	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.59	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.38	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.39	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.32	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.17	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.63	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.17	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.27	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.53	GTP_EFTU
LUAD	chr12	25245328	Missense_Mutation	NA	L19F	0.66	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.49	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.41	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.32	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.32	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.32	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.69	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.35	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.2	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.47	GTP_EFTU
LUAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.21	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.11	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.15	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.25	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.35	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.46	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.21	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.43	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.37	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.62	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.14	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.37	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.35	GTP_EFTU
LUAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.23	GTP_EFTU
LUAD	chr12	25227341	Missense_Mutation	rs17851045	Q61H	0.52	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.28	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12S	0.63	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.87	GTP_EFTU
LUAD	chr12	25227342	Missense_Mutation	rs121913240	Q61L	0.29	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.36	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.25	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.23	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.13	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.28	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.41	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.44	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.25	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.6	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.56	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.24	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.48	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.42	GTP_EFTU
LUAD	chr12	25245348	Missense_Mutation	rs121913535	G13C	0.32	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.17	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.44	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.37	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.16	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.17	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.44	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.19	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.45	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.5	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.16	GTP_EFTU
LUAD	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.5	GTP_EFTU
LUAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.57	GTP_EFTU
LUSC	chr12	25225697	Nonsense_Mutation	novel	R123*	0.08
LUSC	chr12	25209820	3'UTR	novel		0.05
LUSC	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.47	GTP_EFTU
LUSC	chr12	25245345	Missense_Mutation	rs104894365	V14I	0.19	GTP_EFTU
LUSC	chr12	25245348	Missense_Mutation	rs121913535	G13C	0.78	GTP_EFTU
LUSC	chr12	25227341	Missense_Mutation	rs17851045	Q61H	0.4	GTP_EFTU
LUSC	chr12	25225711	Missense_Mutation	NA	C118S	0.49
LUSC	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.12	GTP_EFTU
LUSC	chr12	25245378	Missense_Mutation	novel	E3K	0.38
MESO	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.7	GTP_EFTU
OV	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.39	GTP_EFTU
OV	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.4	GTP_EFTU
OV	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.54	GTP_EFTU
OV	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.6	GTP_EFTU
OV	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.61	GTP_EFTU
OV	chr12	25227342	Missense_Mutation	rs121913240	Q61L	0.13	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.23	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.12	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.24	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.13	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.06	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.06	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.06	GTP_EFTU
PAAD	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.28	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.13	GTP_EFTU
PAAD	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.18	GTP_EFTU
PAAD	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.13	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.04	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.29	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.18	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.21	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.03	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.1	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.52	GTP_EFTU
PAAD	chr12	25227342	Missense_Mutation	rs121913240	Q61R	0.29	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.1	GTP_EFTU
PAAD	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.12	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.08	GTP_EFTU
PAAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.7	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.1	GTP_EFTU
PAAD	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.04	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.32	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.49	GTP_EFTU
PAAD	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.16	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.25	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.13	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.24	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.1	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.31	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.15	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.15	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.06	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.04	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.4	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.58	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.15	GTP_EFTU
PAAD	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.04	GTP_EFTU
PAAD	chr12	25227341	Missense_Mutation	rs17851045	Q61H	0.14	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.25	GTP_EFTU
PAAD	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.24	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.3	GTP_EFTU
PAAD	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.11	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.25	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.21	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.03	GTP_EFTU
PAAD	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.07	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.47	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.29	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.14	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.18	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.05	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.05	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.04	GTP_EFTU
PAAD	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.21	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.53	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.25	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.31	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.2	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.17	GTP_EFTU
PAAD	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.17	GTP_EFTU
PAAD	chr12	25209892	3'UTR	rs794727720		0.38
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.31	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.14	GTP_EFTU
PAAD	chr12	25245348	Missense_Mutation	rs121913535	G13C	0.15	GTP_EFTU
PAAD	chr12	25245349	Silent	NA	G12G	0.15
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.14	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.11	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.26	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.13	GTP_EFTU
PAAD	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.25	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.09	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.07	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.13	GTP_EFTU
PAAD	chr12	25227341	Missense_Mutation	rs17851045	Q61H	0.08	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.38	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.21	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.8	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.19	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.09	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.31	GTP_EFTU
PAAD	chr12	25227342	Missense_Mutation	rs121913240	Q61R	0.19	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.04	GTP_EFTU
PAAD	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.35	GTP_EFTU
PAAD	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.15	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.16	GTP_EFTU
PAAD	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.09	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.21	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.04	GTP_EFTU
PAAD	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.12	GTP_EFTU
PAAD	chr12	25227341	Missense_Mutation	rs17851045	Q61H	0.27	GTP_EFTU
PAAD	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.59	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.12	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.1	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.08	GTP_EFTU
PAAD	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.34	GTP_EFTU
PAAD	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.37	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.28	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.24	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.69	GTP_EFTU
PAAD	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.16	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.08	GTP_EFTU
PAAD	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.12	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.25	GTP_EFTU
PAAD	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.19	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.05	GTP_EFTU
PAAD	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.13	GTP_EFTU
PAAD	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.05	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.07	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.29	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.15	GTP_EFTU
PAAD	chr12	25227341	Missense_Mutation	rs17851045	Q61H	0.2	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.19	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.08	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.12	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.21	GTP_EFTU
PAAD	chr12	25245351	Missense_Mutation	rs121913530	G12S	0.21	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.3	GTP_EFTU
PAAD	chr12	25227338	Silent	novel	E62E	0.44
PAAD	chr12	25227341	Missense_Mutation	rs17851045	Q61H	0.43	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.08	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.04	GTP_EFTU
PAAD	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.13	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.37	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.28	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.12	GTP_EFTU
PAAD	chr12	25227341	Missense_Mutation	rs17851045	Q61H	0.4	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.05	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.1	GTP_EFTU
PAAD	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.33	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.42	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.32	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.09	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.12	GTP_EFTU
PAAD	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.08	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.21	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.16	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.09	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.1	GTP_EFTU
PAAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.22	GTP_EFTU
PRAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.12	GTP_EFTU
PRAD	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.33	GTP_EFTU
READ	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.41	GTP_EFTU
READ	chr12	25227349	Missense_Mutation	rs121913528	A59T	0.27	GTP_EFTU
READ	chr12	25227341	Missense_Mutation	rs17851045	Q61H	0.67	GTP_EFTU
READ	chr12	25227343	Missense_Mutation	rs121913238	Q61E	0.67	GTP_EFTU
READ	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.51	GTP_EFTU
READ	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.41	GTP_EFTU
READ	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.4	GTP_EFTU
READ	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.35	GTP_EFTU
READ	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.79	GTP_EFTU
READ	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.43	GTP_EFTU
READ	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.18	GTP_EFTU
READ	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.3	GTP_EFTU
READ	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.49	GTP_EFTU
READ	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.57	GTP_EFTU
READ	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.76	GTP_EFTU
READ	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.45	GTP_EFTU
READ	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.59	GTP_EFTU
READ	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.6	GTP_EFTU
READ	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.25	GTP_EFTU
READ	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.42	GTP_EFTU
READ	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.48	GTP_EFTU
READ	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.11	GTP_EFTU
READ	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.45	GTP_EFTU
READ	chr12	25245351	Missense_Mutation	rs121913530	G12S	0.79	GTP_EFTU
READ	chr12	25245351	Missense_Mutation	rs121913530	G12S	0.27	GTP_EFTU
READ	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.63	GTP_EFTU
READ	chr12	25227341	Missense_Mutation	rs17851045	Q61H	0.39	GTP_EFTU
READ	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.52	GTP_EFTU
READ	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.3	GTP_EFTU
READ	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.52	GTP_EFTU
READ	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.49	GTP_EFTU
READ	chr12	25227342	Missense_Mutation	rs121913240	Q61L	0.69	GTP_EFTU
READ	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.28	GTP_EFTU
READ	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.41	GTP_EFTU
READ	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.18	GTP_EFTU
READ	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.42	GTP_EFTU
READ	chr12	25225628	Missense_Mutation	rs121913527	A146T	0.69
READ	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.29	GTP_EFTU
READ	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.35	GTP_EFTU
READ	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.23	GTP_EFTU
READ	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.23	GTP_EFTU
READ	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.44	GTP_EFTU
READ	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.29	GTP_EFTU
READ	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.35	GTP_EFTU
READ	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.24	GTP_EFTU
READ	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.93	GTP_EFTU
READ	chr12	25245349	In_Frame_Ins	NA	A11_G12dup	0.37	GTP_EFTU
READ	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.42	GTP_EFTU
READ	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.67	GTP_EFTU
READ	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.26	GTP_EFTU
READ	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.19	GTP_EFTU
READ	chr12	25245351	Missense_Mutation	rs121913530	G12S	0.7	GTP_EFTU
READ	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.45	GTP_EFTU
READ	chr12	25225713	Missense_Mutation	NA	K117N	0.79	GTP_EFTU
READ	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.33	GTP_EFTU
READ	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.69	GTP_EFTU
SARC	chr12	25245348	Missense_Mutation	rs121913535	G13C	0.13	GTP_EFTU
SARC	chr12	25227341	Missense_Mutation	rs17851045	Q61H	0.62	GTP_EFTU
SKCM	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.35	GTP_EFTU
SKCM	chr12	25225713	Missense_Mutation	rs770248150	K117N	0.24	GTP_EFTU
SKCM	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.43	GTP_EFTU
SKCM	chr12	25227340	Missense_Mutation	NA	E62K	0.46	GTP_EFTU
SKCM	chr12	25227342	Missense_Mutation	rs121913240	Q61R	0.46	GTP_EFTU
SKCM	chr12	25227340	Missense_Mutation	NA	E62K	0.5	GTP_EFTU
SKCM	chr12	25227342	Missense_Mutation	rs121913240	Q61L	0.51	GTP_EFTU
SKCM	chr12	25227335	In_Frame_Ins	novel	E63delinsDQ	0.4	GTP_EFTU
SKCM	chr12	25227337	In_Frame_Ins	novel	E62_E63insKYSAMR	0.39	GTP_EFTU
SKCM	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.95	GTP_EFTU
SKCM	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.23	GTP_EFTU
SKCM	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.92	GTP_EFTU
SKCM	chr12	25227343	Missense_Mutation	rs121913238	Q61K	0.53	GTP_EFTU
SKCM	chr12	25227344	Silent	novel	G60G	0.52
SKCM	chr12	25227342	Missense_Mutation	rs121913240	Q61L	0.61	GTP_EFTU
STAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.17	GTP_EFTU
STAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.25	GTP_EFTU
STAD	chr12	25227349	Missense_Mutation	rs121913528	A59T	0.25	GTP_EFTU
STAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.45	GTP_EFTU
STAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.27	GTP_EFTU
STAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.37	GTP_EFTU
STAD	chr12	25227349	Missense_Mutation	rs121913528	A59T	0.31	GTP_EFTU
STAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.34	GTP_EFTU
STAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.33	GTP_EFTU
STAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.17	GTP_EFTU
STAD	chr12	25225628	Missense_Mutation	rs121913527	A146T	0.28
STAD	chr12	25215559	Missense_Mutation	novel	R151T	0.29
STAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.67	GTP_EFTU
STAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.35	GTP_EFTU
STAD	chr12	25245351	Missense_Mutation	rs121913530	G12S	0.55	GTP_EFTU
STAD	chr12	25245351	Missense_Mutation	rs121913530	G12S	0.32	GTP_EFTU
STAD	chr12	25227341	Missense_Mutation	rs17851045	Q61H	0.28	GTP_EFTU
STAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.33	GTP_EFTU
STAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.26	GTP_EFTU
STAD	chr12	25227349	Missense_Mutation	rs121913528	A59T	0.21	GTP_EFTU
STAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.87	GTP_EFTU
STAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.83	GTP_EFTU
STAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.32	GTP_EFTU
STAD	chr12	25225628	Missense_Mutation	rs121913527	A146T	0.67
STAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.48	GTP_EFTU
STAD	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.23	GTP_EFTU
STAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.27	GTP_EFTU
STAD	chr12	25245351	Missense_Mutation	rs121913530	G12S	0.06	GTP_EFTU
STAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.09	GTP_EFTU
STAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.75	GTP_EFTU
STAD	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.31	GTP_EFTU
STAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.23	GTP_EFTU
STAD	chr12	25225628	Missense_Mutation	rs121913527	A146T	0.3
STAD	chr12	25245351	Missense_Mutation	rs121913530	G12S	0.45	GTP_EFTU
STAD	chr12	25227341	Missense_Mutation	rs17851045	Q61H	0.46	GTP_EFTU
STAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.22	GTP_EFTU
STAD	chr12	25225660	Missense_Mutation	NA	R135T	0.05
STAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.23	GTP_EFTU
STAD	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.25	GTP_EFTU
STAD	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.56	GTP_EFTU
TGCT	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.37	GTP_EFTU
TGCT	chr12	25225627	Missense_Mutation	NA	A146V	0.19
TGCT	chr12	25227342	Missense_Mutation	rs121913240	Q61L	0.14	GTP_EFTU
TGCT	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.22	GTP_EFTU
TGCT	chr12	25227342	Missense_Mutation	rs121913240	Q61L	0.12	GTP_EFTU
TGCT	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.17	GTP_EFTU
TGCT	chr12	25227342	Missense_Mutation	rs121913240	Q61R	0.3	GTP_EFTU
TGCT	chr12	25225628	Missense_Mutation	NA	A146P	0.08
TGCT	chr12	25227337	Missense_Mutation	NA	E63K	0.19	GTP_EFTU
TGCT	chr12	25245351	Missense_Mutation	rs121913530	G12S	0.12	GTP_EFTU
TGCT	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.18	GTP_EFTU
TGCT	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.06	GTP_EFTU
TGCT	chr12	25245351	Missense_Mutation	rs121913530	G12R	0.05	GTP_EFTU
THCA	chr12	25227343	Missense_Mutation	rs121913238	Q61K	0.29	GTP_EFTU
THCA	chr12	25227344	Silent	rs397517037	G60G	0.32
THCA	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.39	GTP_EFTU
THCA	chr12	25227342	Missense_Mutation	rs121913240	Q61R	0.34	GTP_EFTU
THYM	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.42	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.41	GTP_EFTU
UCEC	chr12	25208364	3'Flank	novel		0.11
UCEC	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.24	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.2	GTP_EFTU
UCEC	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.62	GTP_EFTU
UCEC	chr12	25204992	3'Flank	novel		0.1
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.46	GTP_EFTU
UCEC	chr12	25245348	Missense_Mutation	rs121913535	G13C	0.51	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.24	GTP_EFTU
UCEC	chr12	25204990	3'Flank	novel		0.27
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.33	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.23	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.31	GTP_EFTU
UCEC	chr12	25208170	3'Flank	novel		0.32
UCEC	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.51	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.41	GTP_EFTU
UCEC	chr12	25205576	3'Flank	novel		0.26
UCEC	chr12	25215520	Missense_Mutation	rs758575947	R164Q	0.41
UCEC	chr12	25204987	3'Flank	novel		0.36
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.52	GTP_EFTU
UCEC	chr12	25208506	3'Flank	novel		0.38
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.24	GTP_EFTU
UCEC	chr12	25225736	Missense_Mutation	NA	P110S	0.27	GTP_EFTU
UCEC	chr12	25209742	3'UTR	novel		0.04
UCEC	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.29	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.17	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.23	GTP_EFTU
UCEC	chr12	25225677	Silent	novel	Q129Q	0.06
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.45	GTP_EFTU
UCEC	chr12	25208506	3'Flank	novel		0.42
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.44	GTP_EFTU
UCEC	chr12	25245348	Missense_Mutation	rs121913535	G13C	0.43	GTP_EFTU
UCEC	chr12	25208215	3'Flank	novel		0.16
UCEC	chr12	25208200	3'Flank	novel		0.41
UCEC	chr12	25209180	3'Flank	novel		0.35
UCEC	chr12	25209835	3'UTR	novel		0.29
UCEC	chr12	25205584	3'Flank	novel		0.2
UCEC	chr12	25208200	3'Flank	novel		0.38
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.16	GTP_EFTU
UCEC	chr12	25205653	3'Flank	novel		0.4
UCEC	chr12	25215520	Missense_Mutation	rs758575947	R164Q	0.07
UCEC	chr12	25206504	3'Flank	novel		0.33
UCEC	chr12	25209743	3'UTR	novel		0.4
UCEC	chr12	25209850	3'UTR	novel		0.29
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.44	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.2	GTP_EFTU
UCEC	chr12	25209682	3'UTR	novel		0.32
UCEC	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.36	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.69	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.59	GTP_EFTU
UCEC	chr12	25245326	Missense_Mutation	NA	T20R	0.12	GTP_EFTU
UCEC	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.41	GTP_EFTU
UCEC	chr12	25208588	3'Flank	novel		0.56
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.32	GTP_EFTU
UCEC	chr12	25208371	3'Flank	novel		0.38
UCEC	chr12	25215499	Frame_Shift_Ins	novel	*I171Nfs14**	0.33
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.44	GTP_EFTU
UCEC	chr12	25208506	3'Flank	novel		0.39
UCEC	chr12	25225627	Missense_Mutation	NA	A146V	0.21
UCEC	chr12	25205529	3'Flank	novel		0.52
UCEC	chr12	25208588	3'Flank	novel		0.52
UCEC	chr12	25227368	Silent	novel	L52L	0.54
UCEC	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.4	GTP_EFTU
UCEC	chr12	25245351	Missense_Mutation	rs121913530	G12S	0.34	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.45	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.38	GTP_EFTU
UCEC	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.85	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.41	GTP_EFTU
UCEC	chr12	25227341	Missense_Mutation	rs17851045	Q61H	0.44	GTP_EFTU
UCEC	chr12	25245351	Missense_Mutation	rs121913530	G12S	0.84	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.44	GTP_EFTU
UCEC	chr12	25206243	3'Flank	novel		0.34
UCEC	chr12	25205339	3'Flank	novel		0.29
UCEC	chr12	25209560	3'UTR	novel		0.34
UCEC	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.21	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.9	GTP_EFTU
UCEC	chr12	25245316	Silent	NA	L23L	0.57
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.31	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.31	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.29	GTP_EFTU
UCEC	chr12	25227341	Missense_Mutation	rs17851045	Q61H	0.33	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.43	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.18	GTP_EFTU
UCEC	chr12	25227341	Missense_Mutation	rs17851045	Q61H	0.72	GTP_EFTU
UCEC	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.35	GTP_EFTU
UCEC	chr12	25208141	3'Flank	novel		0.26
UCEC	chr12	25208459	3'Flank	novel		0.34
UCEC	chr12	25245348	Missense_Mutation	rs121913535	G13C	0.3	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.38	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.31	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.96	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.62	GTP_EFTU
UCEC	chr12	25206242	3'Flank	novel		0.34
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.3	GTP_EFTU
UCEC	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.41	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.75	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.16	GTP_EFTU
UCEC	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.4	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.56	GTP_EFTU
UCEC	chr12	25209869	3'UTR	novel		0.46
UCEC	chr12	25245346	Silent	rs397517040	G13G	0.57
UCEC	chr12	25245347	Missense_Mutation	rs112445441	G13V	0.56	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.4	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.38	GTP_EFTU
UCEC	chr12	25205569	3'Flank	novel		0.38
UCEC	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.37	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.3	GTP_EFTU
UCEC	chr12	25245351	Missense_Mutation	rs121913530	G12S	0.17	GTP_EFTU
UCEC	chr12	25225628	Missense_Mutation	rs121913527	A146T	0.09
UCEC	chr12	25245326	Missense_Mutation	novel	T20K	0.05	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.7	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.77	GTP_EFTU
UCEC	chr12	25208281	3'Flank	novel		0.14
UCEC	chr12	25227236	Splice_Region	novel	Y96Y	0.33
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.16	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.34	GTP_EFTU
UCEC	chr12	25208506	3'Flank	novel		0.29
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.47	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.84	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.22	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.46	GTP_EFTU
UCEC	chr12	25215485	Missense_Mutation	NA	K176Q	0.43
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.43	GTP_EFTU
UCEC	chr12	25245353	In_Frame_Ins	NA	G10dup	0.5	GTP_EFTU
UCEC	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.19	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.29	GTP_EFTU
UCEC	chr12	25227342	Missense_Mutation	rs121913240	Q61L	0.27	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.12	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.48	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.2	GTP_EFTU
UCEC	chr12	25245347	Missense_Mutation	rs112445441	G13D	0.67	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.7	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.29	GTP_EFTU
UCEC	chr12	25227341	Missense_Mutation	rs17851045	Q61H	0.53	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.38	GTP_EFTU
UCEC	chr12	25204979	3'Flank	novel		0.41
UCEC	chr12	25208506	3'Flank	novel		0.48
UCEC	chr12	25209905	3'UTR	NA		0.21
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.54	GTP_EFTU
UCEC	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.41	GTP_EFTU
UCEC	chr12	25206440	3'Flank	novel		0.5
UCEC	chr12	25208356	3'Flank	novel		0.41
UCEC	chr12	25209663	3'UTR	novel		0.34
UCS	chr12	25245350	Missense_Mutation	rs121913529	G12A	0.89	GTP_EFTU
UCS	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.21	GTP_EFTU
UCS	chr12	25245351	Missense_Mutation	rs121913530	G12C	0.77	GTP_EFTU
UCS	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.93	GTP_EFTU
UCS	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.61	GTP_EFTU
UCS	chr12	25245350	Missense_Mutation	rs121913529	G12D	0.67	GTP_EFTU
UCS	chr12	25245350	Missense_Mutation	rs121913529	G12V	0.44	GTP_EFTU

Copy Number Variations (CNVs)

Cancer	Type	Freq	Q-value
BLCA	AMP	0.2623	0.05329
ESCA	AMP	0.375	7.5822e-11
LUAD	AMP	0.2713	1.8018e-12
OV	AMP	0.506	7.6963e-12
READ	AMP	0.2182	0.0023433
READ	DEL	0.0848	0.064633
STAD	AMP	0.2268	2.4608e-34
TGCT	AMP	0.9467	1.4729e-22
UCEC	AMP	0.141	0.021114

Survival Analysis

Cancer	P-value	Q-value
THYM	0.0031	Kaplan-Meier Survival Analysis
KIRC	0.0003	Kaplan-Meier Survival Analysis
SARC	0.013	Kaplan-Meier Survival Analysis
MESO	0.0028	Kaplan-Meier Survival Analysis
ACC	0.0011	Kaplan-Meier Survival Analysis
ESCA	0.0082	Kaplan-Meier Survival Analysis
PAAD	0.00015	Kaplan-Meier Survival Analysis
CESC	0.028	Kaplan-Meier Survival Analysis
UCEC	0.0094	Kaplan-Meier Survival Analysis
LIHC	0.016	Kaplan-Meier Survival Analysis
CHOL	0.027	Kaplan-Meier Survival Analysis
LUAD	0.003	Kaplan-Meier Survival Analysis

Drugs

EuRBPDB

Description

RBDs

Literatures

Expression

Transcripts

Gene Model

Pathways

Phenotypes

PPI

Orthologs

Gene Ontology

Select Dataset :

Input Drug :

Input Cell Line :

Eesembl ID

Cell lines and drugs in GSE70138 or GSE92742